U.S. patent application number 14/887073 was filed with the patent office on 2016-02-18 for thermophilic and thermoacidophilic metabolism genes and enzymes from alicyclobacillus acidocaldarius and related organisms, methods.
The applicant listed for this patent is Battelle Energy Alliance, LLC.. Invention is credited to William A. Apel, Jeffrey A. Lacey, Brady D. Lee, David W. Reed, Francisco F. Roberto, David N. Thompson, Vicki S. Thompson.
Application Number | 20160046911 14/887073 |
Document ID | / |
Family ID | 41215393 |
Filed Date | 2016-02-18 |
United States Patent
Application |
20160046911 |
Kind Code |
A1 |
Thompson; Vicki S. ; et
al. |
February 18, 2016 |
THERMOPHILIC AND THERMOACIDOPHILIC METABOLISM GENES AND ENZYMES
FROM ALICYCLOBACILLUS ACIDOCALDARIUS AND RELATED ORGANISMS,
METHODS
Abstract
Isolated and/or purified polypeptides and nucleic acid sequences
encoding polypeptides from Alicyclobacillus acidocaldarius are
provided. Further provided are methods for modulating or altering
metabolism in a cell using isolated and/or purified polypeptides
and nucleic acid sequences from Alicyclobacillus
acidocaldarius.
Inventors: |
Thompson; Vicki S.; (Idaho
Falls, ID) ; Apel; William A.; (Jackson, WY) ;
Reed; David W.; (Idaho Falls, ID) ; Lee; Brady
D.; (West Richland, WA) ; Thompson; David N.;
(Idaho Falls, ID) ; Roberto; Francisco F.;
(Highlands Ranch, CO) ; Lacey; Jeffrey A.; (Idaho
Falls, ID) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Battelle Energy Alliance, LLC. |
Idaho Falls |
ID |
US |
|
|
Family ID: |
41215393 |
Appl. No.: |
14/887073 |
Filed: |
October 19, 2015 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14226573 |
Mar 26, 2014 |
9222094 |
|
|
14887073 |
|
|
|
|
12380551 |
Feb 26, 2009 |
8728803 |
|
|
14226573 |
|
|
|
|
61032339 |
Feb 28, 2008 |
|
|
|
Current U.S.
Class: |
435/455 ;
435/320.1; 435/471 |
Current CPC
Class: |
C12Y 203/01009 20130101;
C12Y 402/01055 20130101; C12N 9/1029 20130101; C12N 15/75 20130101;
C12N 9/00 20130101; C12N 15/74 20130101; C12N 9/88 20130101 |
International
Class: |
C12N 9/10 20060101
C12N009/10 |
Goverment Interests
GOVERNMENT RIGHTS
[0002] This invention was made with government support under
Contract Number DE-AC07-991D13727 and Contract Number
DE-AC07-051D14517 awarded by the United States Department of
Energy. The government has certain rights in the invention. [0003]
(long sequence listing--with parent (Filed with Request to Transfer
CRF))
Claims
1. An expression vector comprising an isolated polynucleotide
encoding a polypeptide having at least 90% sequence identity to SEQ
ID No. 392.
2. The expression vector of claim 1, wherein the expression vector
comprises a polynucleotide having at least 90% identity to SEQ ID
No. 393.
3. The expression vector of claim 1, wherein the encoded
polypeptide has Acetyl-CoA C-acetyltransferase enzymatic
activity.
4. A method of modulating or altering metabolism in a cell, the
method comprising: providing the expression vector of claim 3 to
the cell and expressing the encoded polypeptide in the cell.
5. The method according to claim 4, further comprising
glycosylating, or otherwise post-translationally modifying the
encoded peptide in the cell.
6. An expression vector comprising an isolated polynucleotide
encoding a polypeptide having at least 95% sequence identity to SEQ
ID No. 392.
7. The expression vector of claim 6, wherein the encoded
polypeptide has Acetyl-CoA C-acetyltransferase enzymatic
activity.
8. The expression vector of claim 6, wherein the expression vector
comprises a polynucleotide having at least 95% identity to SEQ ID
No. 393.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a divisional of U.S. patent application
Ser. No. 14/226,573, filed Mar. 26, 2014, pending, which is a
divisional of U.S. patent application Ser. No. 12/380,551, filed
Feb. 26, 2009, now U.S. Pat. No. 8,728,803, issued May 20, 2014,
which application claims the benefit of the filing date of U.S.
Provisional Patent Application Ser. No. 61/032,339, filed Feb. 28,
2008, for "THERMOPHILIC AND THERMOACIDOPHILIC METABOLISM GENES AND
ENZYMES FROM ALICYCLOBACILLUS ACIDOCALDARIUS AND RELATED ORGANISMS,
METHODS," the disclosure of each of which is hereby incorporated
herein in its entirety by this reference.
STATEMENT ACCORDING TO 37 C.F.R. .sctn.1.821(c) or (e)--SEQUENCE
LISTING SUBMITTED AS PDF FILE WITH A REQUEST TO TRANSFER CRF FROM
PARENT APPLICATION
[0004] Pursuant to 37 C.F.R. .sctn.1.821(c) or (e), a file
containing a PDF version of the Sequence Listing has been submitted
concomitant with this application, the contents of which are hereby
incorporated by reference. The transmittal documents of this
application include a Request to Transfer CRF from the parent
application.
TECHNICAL FIELD
[0005] The present invention relates generally to biotechnology.
More specifically, embodiments of the present invention relate to
isolated and/or purified polypeptides and nucleic acid sequences
encoding polypeptides from Alicyclobacillus acidocaldarius and
methods for their use.
BACKGROUND
[0006] Enzymes have a great deal of potential for production of
useful chemicals in industrial processes. However, industrial
processes typically occur at extremes of temperature, pH, salt,
etc., to which most of the well-studied enzymes and organisms are
not well suited.
BRIEF SUMMARY OF THE INVENTION
[0007] Embodiments of the invention relate to purified and/or
isolated nucleotide sequences of the genome of Alicyclobacillus
acidocaldarius, or a homologue or fragment thereof. In one
embodiment of the invention, the nucleotide sequence is selected
from at least one of SEQ ID NOS:2, 19, 36, 53, 70, 87, 104, 121,
138, 155, 172, 189, 206, 223, 240, 257, 274, 291, 308, 325, 342,
359, 376, 393, 410, 427, 444, 461, 478, 495, 512, 529, 546, 563,
580, 597, 614, 631, 648, 665, 682, 699, 716, 733, 750, 767, 784,
801, 818, 835, 852, 869, 886, 903, 920, 937, 954, 971, 988, 1005,
1022, 1039, 1056, 1073, 1090, 1107, 1124, 1141, 1158, 1175, 1192,
1209, 1226, 1243, 1260, 1277, 1294, 1311, 1328, 1345, 1362, 1379,
1396, 1413, 1430, 1447, 1464, 1481, 1498, 1515, 1532, 1549, and
1566 or a homologue or fragment thereof. In another embodiment of
the invention, the homologue is selected from the group consisting
of a nucleotide sequence having at least 80% sequence identity to
at least one of SEQ ID NOS:2, 19, 36, 53, 70, 87, 104, 121, 138,
155, 172, 189, 206, 223, 240, 257, 274, 291, 308, 325, 342, 359,
376, 393, 410, 427, 444, 461, 478, 495, 512, 529, 546, 563, 580,
597, 614, 631, 648, 665, 682, 699, 716, 733, 750, 767, 784, 801,
818, 835, 852, 869, 886, 903, 920, 937, 954, 971, 988, 1005, 1022,
1039, 1056, 1073, 1090, 1107, 1124, 1141, 1158, 1175, 1192, 1209,
1226, 1243, 1260, 1277, 1294, 1311, 1328, 1345, 1362, 1379, 1396,
1413, 1430, 1447, 1464, 1481, 1498, 1515, 1532, 1549, and 1566.
[0008] Embodiments of the invention may further relate to an
isolated and/or purified nucleic acid sequence comprising a nucleic
acid sequence encoding a polypeptide selected from the group
consisting of a polypeptide having at least 90% sequence identity
to at least one of SEQ ID NOS:1, 18, 35, 52, 69, 86, 103, 120, 137,
154, 171, 188, 205, 222, 239, 256, 273, 290, 307, 324, 341, 358,
375, 392, 409, 426, 443, 460, 477, 494, 511, 528, 545, 562, 579,
596, 613, 630, 647, 664, 681, 698, 715, 732, 749, 766, 783, 800,
817, 834, 851, 868, 885, 902, 819, 936, 953, 970, 987, 1004, 1021,
1038, 1055, 1072, 1089, 1106, 1123, 1140, 1157, 1174, 1191, 1208,
1225, 1242, 1259, 1276, 1293, 1310, 1327, 1344, 1361, 1378, 1395,
1412, 1429, 1446, 1463, 1480, 1497, 1514, 1531, 1548, and 1565.
[0009] Embodiments of the invention also relate to isolated and/or
purified polypeptides coded for by a nucleotide sequence comprising
a nucleotide sequence of the genome of Alicyclobacillus
acidocaldarius, or a homologue or fragment thereof. In one
embodiment, the nucleotide sequence comprises a nucleotide sequence
selected from the group consisting of a nucleotide sequence having
at least 80% sequence identity to at least one of SEQ ID NOS:2, 19,
36, 53, 70, 87, 104, 121, 138, 155, 172, 189, 206, 223, 240, 257,
274, 291, 308, 325, 342, 359, 376, 393, 410, 427, 444, 461, 478,
495, 512, 529, 546, 563, 580, 597, 614, 631, 648, 665, 682, 699,
716, 733, 750, 767, 784, 801, 818, 835, 852, 869, 886, 903, 920,
937, 954, 971, 988, 1005, 1022, 1039, 1056, 1073, 1090, 1107, 1124,
1141, 1158, 1175, 1192, 1209, 1226, 1243, 1260, 1277, 1294, 1311,
1328, 1345, 1362, 1379, 1396, 1413, 1430, 1447, 1464, 1481, 1498,
1515, 1532, 1549, and 1566.
[0010] In another embodiment of the invention, the nucleotide
sequence comprises a nucleotide sequence selected from at least one
of SEQ ID NOS:2, 19, 36, 53, 70, 87, 104, 121, 138, 155, 172, 189,
206, 223, 240, 257, 274, 291, 308, 325, 342, 359, 376, 393, 410,
427, 444, 461, 478, 495, 512, 529, 546, 563, 580, 597, 614, 631,
648, 665, 682, 699, 716, 733, 750, 767, 784, 801, 818, 835, 852,
869, 886, 903, 920, 937, 954, 971, 988, 1005, 1022, 1039, 1056,
1073, 1090, 1107, 1124, 1141, 1158, 1175, 1192, 1209, 1226, 1243,
1260, 1277, 1294, 1311, 1328, 1345, 1362, 1379, 1396, 1413, 1430,
1447, 1464, 1481, 1498, 1515, 1532, 1549, and 1566 or a homologue
or fragment thereof. In still another embodiment, the polypeptide
comprises an amino acid sequence of SEQ ID NOS:1, 18, 35, 52, 69,
86, 103, 120, 137, 154, 171, 188, 205, 222, 239, 256, 273, 290,
307, 324, 341, 358, 375, 392, 409, 426, 443, 460, 477, 494, 511,
528, 545, 562, 579, 596, 613, 630, 647, 664, 681, 698, 715, 732,
749, 766, 783, 800, 817, 834, 851, 868, 885, 902, 819, 936, 953,
970, 987, 1004, 1021, 1038, 1055, 1072, 1089, 1106, 1123, 1140,
1157, 1174, 1191, 1208, 1225, 1242, 1259, 1276, 1293, 1310, 1327,
1344, 1361, 1378, 1395, 1412, 1429, 1446, 1463, 1480, 1497, 1514,
1531, 1548, and 1565. In yet another embodiment, the polypeptide
comprises an amino acid sequence selected from the group consisting
of a polypeptide having at least 90% sequence identity to at least
one of SEQ ID NOS:1, 18, 35, 52, 69, 86, 103, 120, 137, 154, 171,
188, 205, 222, 239, 256, 273, 290, 307, 324, 341, 358, 375, 392,
409, 426, 443, 460, 477, 494, 511, 528, 545, 562, 579, 596, 613,
630, 647, 664, 681, 698, 715, 732, 749, 766, 783, 800, 817, 834,
851, 868, 885, 902, 819, 936, 953, 970, 987, 1004, 1021, 1038,
1055, 1072, 1089, 1106, 1123, 1140, 1157, 1174, 1191, 1208, 1225,
1242, 1259, 1276, 1293, 1310, 1327, 1344, 1361, 1378, 1395, 1412,
1429, 1446, 1463, 1480, 1497, 1514, 1531, 1548, and 1565.
[0011] In embodiments of the invention, the polypeptides may be
acidophilic and/or thermophilic. In further embodiments, the
polypeptides may be glycosylated, pegylated, and/or otherwise
post-translationally modified.
[0012] Embodiments of methods include methods of altering
metabolism in a cell, the methods comprising providing a
recombinant, purified, and/or isolated nucleotide sequence
comprising a nucleotide sequence selected from the group consisting
of a nucleotide sequence having at least 90% sequence identity to
at least one of the sequences of SEQ ID NOS:2, 19, 36, 53, 70, 87,
104, 121, 138, 155, 172, 189, 206, 223, 240, 257, 274, 291, 308,
325, 342, 359, 376, 393, 410, 427, 444, 461, 478, 495, 512, 529,
546, 563, 580, 597, 614, 631, 648, 665, 682, 699, 716, 733, 750,
767, 784, 801, 818, 835, 852, 869, 886, 903, 920, 937, 954, 971,
988, 1005, 1022, 1039, 1056, 1073, 1090, 1107, 1124, 1141, 1158,
1175, 1192, 1209, 1226, 1243, 1260, 1277, 1294, 1311, 1328, 1345,
1362, 1379, 1396, 1413, 1430, 1447, 1464, 1481, 1498, 1515, 1532,
1549, and 1566 and/or a recombinant, purified, and/or isolated
polypeptide selected from the group consisting of a polypeptide
having at least 90% sequence identity to at least one of the
sequences of SEQ ID NOS:1, 18, 35, 52, 69, 86, 103, 120, 137, 154,
171, 188, 205, 222, 239, 256, 273, 290, 307, 324, 341, 358, 375,
392, 409, 426, 443, 460, 477, 494, 511, 528, 545, 562, 579, 596,
613, 630, 647, 664, 681, 698, 715, 732, 749, 766, 783, 800, 817,
834, 851, 868, 885, 902, 819, 936, 953, 970, 987, 1004, 1021, 1038,
1055, 1072, 1089, 1106, 1123, 1140, 1157, 1174, 1191, 1208, 1225,
1242, 1259, 1276, 1293, 1310, 1327, 1344, 1361, 1378, 1395, 1412,
1429, 1446, 1463, 1480, 1497, 1514, 1531, 1548, and 1565 to the
cell.
[0013] Further embodiments of methods include placing a cell
producing or encoding a recombinant, purified, and/or isolated
nucleotide sequence comprising a nucleotide sequence selected from
the group consisting of a nucleotide sequence having at least 90%
sequence identity to at least one of the sequences of SEQ ID NOS:2,
19, 36, 53, 70, 87, 104, 121, 138, 155, 172, 189, 206, 223, 240,
257, 274, 291, 308, 325, 342, 359, 376, 393, 410, 427, 444, 461,
478, 495, 512, 529, 546, 563, 580, 597, 614, 631, 648, 665, 682,
699, 716, 733, 750, 767, 784, 801, 818, 835, 852, 869, 886, 903,
920, 937, 954, 971, 988, 1005, 1022, 1039, 1056, 1073, 1090, 1107,
1124, 1141, 1158, 1175, 1192, 1209, 1226, 1243, 1260, 1277, 1294,
1311, 1328, 1345, 1362, 1379, 1396, 1413, 1430, 1447, 1464, 1481,
1498, 1515, 1532, 1549, and 1566 and/or a recombinant, purified,
and/or isolated polypeptide selected from the group consisting of a
polypeptide having at least 90% sequence identity to at least one
of the sequences of SEQ ID NOS:1, 18, 35, 52, 69, 86, 103, 120,
137, 154, 171, 188, 205, 222, 239, 256, 273, 290, 307, 324, 341,
358, 375, 392, 409, 426, 443, 460, 477, 494, 511, 528, 545, 562,
579, 596, 613, 630, 647, 664, 681, 698, 715, 732, 749, 766, 783,
800, 817, 834, 851, 868, 885, 902, 819, 936, 953, 970, 987, 1004,
1021, 1038, 1055, 1072, 1089, 1106, 1123, 1140, 1157, 1174, 1191,
1208, 1225, 1242, 1259, 1276, 1293, 1310, 1327, 1344, 1361, 1378,
1395, 1412, 1429, 1446, 1463, 1480, 1497, 1514, 1531, 1548, and
1565 in an environment comprising temperatures at or above about
25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, and/or 95
degrees Celsius and/or a pH at, below, and/or above 8, 7, 6, 5, 4,
3, 2, 1, and/or 0.
[0014] These and other aspects of the invention will become
apparent to the skilled artisan in view of the teachings contained
herein.
BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS
[0015] FIGS. 1A and 1B depict a sequence alignment between SEQ ID
NO:1 (RAAC00079) and ref|YP.sub.--074710.1|,
ref|YP.sub.--359514.1|, ref|YP.sub.--516748.1|,
ref|YP.sub.--643635.1|, and ref|YP.sub.--144514.1| (SEQ ID NOS:3-7,
respectively), which all have the function assigned to SEQ ID NO:1
in Table 1. Amino acids conserved among all sequences are indicted
by a "*" and generally conserved amino acids are indicated by a
":".
[0016] FIG. 2 depicts a sequence alignment between SEQ ID NO:18
(RAAC00455) and gb|ABE97159.1|, ref|NP.sub.--693902.1|,
ref|YP.sub.--521150.1|, ref|ZP.sub.--01725542.1|, and
ref|ZP.sub.--01666741.1| (SEQ ID NOS:20-24, respectively), which
all have the function assigned to SEQ ID NO:18 in Table 1. Amino
acids conserved among all sequences are indicted by a "*" and
generally conserved amino acids are indicated by a ":".
[0017] FIGS. 3A and 3B depict a sequence alignment between SEQ ID
NO:35 (RAAC00461) and ref|YP.sub.--361350.1,
ref|NP.sub.--244632.1|, ref|ZP.sub.--00538452.1|,
ref|YP.sub.--001127398.1|, and ref|YP.sub.--149222.1| (SEQ ID
NOS:37-41, respectively), which all have the function assigned to
SEQ ID NO:35 in Table 1. Amino acids conserved among all sequences
are indicted by a "*" and generally conserved amino acids are
indicated by a ":".
[0018] FIG. 4 depicts a sequence alignment between SEQ ID NO:52
(RAAC00481) and ref|NP.sub.--905294.1|, ref|ZP01666099.1|,
ref|YP.sub.--360429.1|, ref|YP.sub.--754604.1|, and
ref|YP.sub.--384529.11 (SEQ ID NOS:54-58, respectively), which all
have the function assigned to SEQ ID NO:52 in Table 1. Amino acids
conserved among all sequences are indicted by a "*" and generally
conserved amino acids are indicated by a ":".
[0019] FIG. 5 depicts a sequence alignment between SEQ ID NO:69
(RAAC00529) and ref|YP.sub.--146903.1|, ref|YP.sub.--001125035.1|,
ref|YP.sub.--001646604.1|, ref|YP.sub.--001375911.1|, and
ref_ZP.sub.--01696300.1| (SEQ ID NOS:71-75, respectively), which
all have the function assigned to SEQ ID NO:69 in Table 1. Amino
acids conserved among all sequences are indicted by a "*" and
generally conserved amino acids are indicated by a ":".
[0020] FIG. 6 depicts a sequence alignment between SEQ ID NO:86
(RAAC00552) and ref|YP.sub.--001376041.1|, dbj|BAB39458.1|,
ref|NP.sub.--846569.1|, ref|YP.sub.--896466.1|, and
ref|ZP.sub.--00238879.1| (SEQ ID NOS:88-92, respectively), which
all have the function assigned to SEQ ID NO:86 in Table 1. Amino
acids conserved among all sequences are indicted by a "*" and
generally conserved amino acids are indicated by a ":".
[0021] FIG. 7 depicts a sequence alignment between SEQ ID NO:103
(RAAC00553) and ref|YP.sub.--001646745.1|,
ref|YP.sub.--001376045.1|, ref|NP.sub.--833836.1|,
ref|ZP.sub.--00739346.1|, and ref|YP.sub.--085454.1| (SEQ ID
NOS:105-109, respectively), which all have the function assigned to
SEQ ID NO:103 in Table 1. Amino acids conserved among all sequences
are indicted by a "*" and generally conserved amino acids are
indicated by a ":".
[0022] FIG. 8 depicts a sequence alignment between SEQ ID NO:120
(RAAC00554) and ref|YP.sub.--147981.1|, ref|NP.sub.--390900.1|,
ref|ZP.sub.--01667656.1|, sp|P22806|BIOF_BACSH, and dbj|BAB39457.1|
(SEQ ID NOS:122-126, respectively), which all have the function
assigned to SEQ ID NO:120 in Table 1. Amino acids conserved among
all sequences are indicted by a "*" and generally conserved amino
acids are indicated by a ":".
[0023] FIG. 9 depicts a sequence alignment between SEQ ID NO:137
(RAAC00632) and ref|YP.sub.--001126681.1|, ref|YP.sub.--148515.1|,
ref|ZP.sub.--01171798.1|, ref|YP.sub.--001374758.1|, and
ref|YP.sub.--080106.1| (SEQ ID NOS:139-143, respectively), which
all have the function assigned to SEQ ID NO:137 in Table 1. Amino
acids conserved among all sequences are indicted by a "*" and
generally conserved amino acids are indicated by a ":".
[0024] FIGS. 10A and 10B depict a sequence alignment between SEQ ID
NO:154 (RAAC00633) and ref|NP.sub.--243928.1|,
ref|ZP.sub.--01695378.1|, ref|ZP.sub.--01725506.1|,
ref|YP.sub.--176142.1|, and ref|YP.sub.--850199.1| (SEQ ID
NOS:156-160, respectively), which all have the function assigned to
SEQ ID NO:154 in Table 1. Amino acids conserved among all sequences
are indicted by a "*" and generally conserved amino acids are
indicated by a ":".
[0025] FIGS. 11A and 11B depict a sequence alignment between SEQ ID
NO:171 (RAAC00634) and ref|YP.sub.--001126680.1|,
ref|YP.sub.--001487695.1|, ref|YP.sub.--148514.1|, gb|AAL99356.1|,
and ref|YP.sub.--176141.1| (SEQ ID NOS:173-177, respectively),
which all have the function assigned to SEQ ID NO:171 in Table 1.
Amino acids conserved among all sequences are indicted by a "*" and
generally conserved amino acids are indicated by a ":".
[0026] FIG. 12 depicts a sequence alignment between SEQ ID NO:188
(RAAC00174) and ref|YP.sub.--175798.1|, ref|NP.sub.--243358.1|,
ref|NP.sub.--389472.1|, ref|ZP.sub.--01861659.1|, and
ref|YP.sub.--147042.1| (SEQ ID NOS:190-194, respectively), which
all have the function assigned to SEQ ID NO:188 in Table 1. Amino
acids conserved among all sequences are indicted by a "*" and
generally conserved amino acids are indicated by a ":".
[0027] FIG. 13 depicts a sequence alignment between SEQ ID NO:205
(RAAC00635) and ref|YP.sub.--148513.1|, ref|NP.sub.--243926.1|,
ref|YP.sub.--001126679.1|, ref|YP.sub.--176140.1|, and
ref|NP.sub.--843875.1| (SEQ ID NOS:207-211, respectively), which
all have the function assigned to SEQ ID NO:205 in Table 1. Amino
acids conserved among all sequences are indicted by a "*" and
generally conserved amino acids are indicated by a ":".
[0028] FIG. 14 depicts a sequence alignment between SEQ ID NO:222
(RAAC00637) and ref|NP.sub.--243923.1|, ref|YP.sub.--148510.1|,
ref|ZP.sub.--01171803.1|, ref|YP.sub.--001126676.1|, and
ref|NP.sub.--926497.1| (SEQ ID NOS:224-228, respectively), which
all have the function assigned to SEQ ID NO:222 in Table 1. Amino
acids conserved among all sequences are indicted by a "*" and
generally conserved amino acids are indicated by a ":".
[0029] FIGS. 15A and 15B depict a sequence alignment between SEQ ID
NO:239 (RAAC00638) and ref|NP.sub.--243922.1|,
ref|YP.sub.--148509.1|, ref|YP.sub.--001126675.1|,
ref|ZP.sub.--01171804.1|, and ref|YP.sub.--075945.1| (SEQ ID
NOS:241-245, respectively), which all have the function assigned to
SEQ ID NO:239 in Table 1. Amino acids conserved among all sequences
are indicted by a "*" and generally conserved amino acids are
indicated by a ":".
[0030] FIG. 16 depicts a sequence alignment between SEQ ID NO:256
(RAAC00639) and sp|Q67MJ3|LEUD_SYMTH, ref|YP.sub.--148508.1|,
ref|YP.sub.--001126674.1|, ref|YP.sub.--080099.1|, and
ref|YP.sub.--001487689.1| (SEQ ID NOS:258-262, respectively), which
all have the function assigned to SEQ ID NO:256 in Table 1. Amino
acids conserved among all sequences are indicted by a "*" and
generally conserved amino acids are indicated by a ":".
[0031] FIGS. 17A and 17B depict a sequence alignment between SEQ ID
NO:273 (RAAC00642) and ref|YP.sub.--826036.1|, gb|ABV27286.1|,
gb|AAL17866.1|AF424980.sub.--1, ref|ZP.sub.--01859643.1|, and
ref|NP.sub.--244026.1| (SEQ ID NOS:275-279, respectively), which
all have the function assigned to SEQ ID NO:273 in Table 1. Amino
acids conserved among all sequences are indicted by a "*" and
generally conserved amino acids are indicated by a ":".
[0032] FIGS. 18A-18C depict a sequence alignment between SEQ ID
NO:290 (RAAC00727) and ref|YP.sub.--001637294.1|,
ref|ZP.sub.--01516643.1|, ref|YP.sub.--645264.1|,
ref|YP.sub.--146876.1|, and ref|YP.sub.--001125008.1| (SEQ ID
NOS:292-296, respectively), which all have the function assigned to
SEQ ID NO:290 in Table 1. Amino acids conserved among all sequences
are indicted by a "*" and generally conserved amino acids are
indicated by a ":".
[0033] FIGS. 19A and 19B depict a sequence alignment between SEQ ID
NO:307 (RAAC00729) and ref|YP.sub.--001125365.1|,
ref|YP.sub.--147249.1|, ref|ZP.sub.--01695431.1|,
ref|NP.sub.--244828.1|, and ref|YP.sub.--895448.1| (SEQ ID
NOS:309-313, respectively), which all have the function assigned to
SEQ ID NO:307 in Table 1. Amino acids conserved among all sequences
are indicted by a "*" and generally conserved amino acids are
indicated by a ":".
[0034] FIGS. 20A and 20B depict a sequence alignment between SEQ ID
NO:324 (RAAC00730) and ref|YP.sub.--075148.1|,
sp|P164681MAOX_BACST, ref|YP.sub.--147293.1|,
ref|YP.sub.--643888.1|, and ref|YP.sub.--001125416.1| (SEQ ID
NOS:326-330, respectively), which all have the function assigned to
SEQ ID NO:324 in Table 1. Amino acids conserved among all sequences
are indicted by a "*" and generally conserved amino acids are
indicated by a ":".
[0035] FIGS. 21A-21C depict a sequence alignment between SEQ ID
NO:341 (RAAC00735) and ref|ZP.sub.--01696337.1|,
ref|ZP.sub.--02171753.1, ref|YP.sub.--284976.1|,
ref|YP.sub.--001546997.1|, and ref|YP.sub.--001277075.1| (SEQ ID
NOS:343-347, respectively), which all have the function assigned to
SEQ ID NO:341 in Table 1. Amino acids conserved among all sequences
are indicted by a "*" and generally conserved amino acids are
indicated by a ":".
[0036] FIG. 22 depicts a sequence alignment between SEQ ID NO:358
(RAAC00812) and ref|ZP.sub.--00539373.1|, ref|YP.sub.--386234.1|,
ref|YP.sub.--001378696.1|, ref|ZP01723286.1|, and
ref|NP.sub.--91778.1| (SEQ ID NOS:360-364, respectively), which all
have the function assigned to SEQ ID NO:358 in Table 1. Amino acids
conserved among all sequences are indicted by a "*" and generally
conserved amino acids are indicated by a ":".
[0037] FIGS. 23A and 23B depict a sequence alignment between SEQ ID
NO:375 (RAAC00196) and ref|YP.sub.--147293.1|,
sp|P16468|MAOX_BACST, ref|YP.sub.--643888.1|,
ref|YP.sub.--075148.1|, and ref|YP.sub.--001125416.1| (SEQ ID
NOS:377-381, respectively), which all have the function assigned to
SEQ ID NO:375 in Table 1. Amino acids conserved among all sequences
are indicted by a "*" and generally conserved amino acids are
indicated by a ":".
[0038] FIG. 24 depicts a sequence alignment between SEQ ID NO:392
(RAAC00814) and ref|YP.sub.--360188.1|, ref|ZP.sub.--01666093.1|,
ref|NP.sub.--242895.1|, ref|YP.sub.--60122.1|, and
ref|ZP.sub.--01372991.1| (SEQ ID NOS:394-398, respectively), which
all have the function assigned to SEQ ID NO:392 in Table 1. Amino
acids conserved among all sequences are indicted by a "*" and
generally conserved amino acids are indicated by a ":".
[0039] FIGS. 25A and 25B depict a sequence alignment between SEQ ID
NO:409 (RAAC00815) and ref|YP.sub.--644483.1|,
ref|NP.sub.--294183.1|, ref|YP.sub.--359514.1|,
ref|YP.sub.--605214.1|, and ref|YP.sub.--592595.1| (SEQ ID
NOS:411-415, respectively), which all have the function assigned to
SEQ ID NO:409 in Table 1. Amino acids conserved among all sequences
are indicted by a "*" and generally conserved amino acids are
indicated by a ":".
[0040] FIG. 26 depicts a sequence alignment between SEQ ID NO:426
(RAAC00816) and ref|YP.sub.--147450.1|, ref|YP.sub.--001125561.1|,
ref|ZP.sub.--01696479.1|, ref|NP.sub.--241996.1|, and
ref|YP.sub.--079308.1| (SEQ ID NOS:428-432, respectively), which
all have the function assigned to SEQ ID NO:426 in Table 1. Amino
acids conserved among all sequences are indicted by a "*" and
generally conserved amino acids are indicated by a ":".
[0041] FIG. 27 depicts a sequence alignment between SEQ ID NO:443
(RAAC00822) and ref|ZP.sub.--00539140.1, ref|ZP.sub.--02130394.1|,
ref|NP.sub.--241073.1|, ref|ZP.sub.--01696475.1|, and
dbj|BAA75325.1| (SEQ ID NOS:445-449, respectively), which all have
the function assigned to SEQ ID NO:443 in Table 1. Amino acids
conserved among all sequences are indicted by a "*" and generally
conserved amino acids are indicated by a ":".
[0042] FIGS. 28A-28C depict a sequence alignment between SEQ ID
NO:460 (RAAC00950) and ref|YP.sub.--001420821.1|,
ref|ZP.sub.--01696606.1|, ref|ZP.sub.--01171726.1|,
ref|NP.sub.--389098.1|, and ref|YP.sub.--091797.1| (SEQ ID
NOS:462-466, respectively), which all have the function assigned to
SEQ ID NO:460 in Table 1. Amino acids conserved among all sequences
are indicted by a "*" and generally conserved amino acids are
indicated by a ":".
[0043] FIG. 29 depicts a sequence alignment between SEQ ID NO:477
(RAAC00952) and ref|YP.sub.--146314.1|, ref|YP.sub.--001124593.1|,
ref|NP.sub.--830405.1|, ref|ZP.sub.--00739906.1|, and
ref|NP.sub.--391552.1| (SEQ ID NOS:479-483, respectively), which
all have the function assigned to SEQ ID NO:477 in Table 1. Amino
acids conserved among all sequences are indicted by a "*" and
generally conserved amino acids are indicated by a ":".
[0044] FIG. 30 depicts a sequence alignment between SEQ ID NO:494
(RAAC00990) and ref|YP.sub.--148038.1|, ref|YP.sub.--001126216.1|,
ref|NP.sub.--242546.1|, ref|ZP.sub.--01697215.1|, and
ref|YP.sub.--175412.1| (SEQ ID NOS:496-500, respectively), which
all have the function assigned to SEQ ID NO:494 in Table 1. Amino
acids conserved among all sequences are indicted by a "*" and
generally conserved amino acids are indicated by a ":".
[0045] FIG. 31 depicts a sequence alignment between SEQ ID NO:511
(RAAC01029) and ref|YP.sub.--001132791.1|, ref|YP.sub.--890165.1|,
ref|YP.sub.--704478.1|, ref|YP.sub.--956012.1|, and
ref|YP.sub.--879906.21 (SEQ ID NOS:513-517, respectively), which
all have the function assigned to SEQ ID NO:511 in Table 1. Amino
acids conserved among all sequences are indicted by a "*" and
generally conserved amino acids are indicated by a ":".
[0046] FIGS. 32A-32C depict a sequence alignment between SEQ ID
NO:528 (RAAC01041) and ref|YP.sub.--359304.1|,
ref|ZP.sub.--01697277.1|, ref|YP.sub.--519313.1|,
ref|ZP.sub.--01370069.1|, and ref|YP.sub.--429480.1| (SEQ ID
NOS:530-534, respectively), which all have the function assigned to
SEQ ID NO:528 in Table 1. Amino acids conserved among all sequences
are indicted by a "*" and generally conserved amino acids are
indicated by a ":".
[0047] FIGS. 33A and 33B depict a sequence alignment between SEQ ID
NO:545 (RAAC01057) and ref|YP.sub.--148861.1|,
ref|YP.sub.--076839.1|, ref|NP.sub.--244355.1|,
ref|ZP.sub.--01697463.1|, and ref|ZP.sub.--01173543.1| (SEQ ID
NOS:547-551, respectively), which all have the function assigned to
SEQ ID NO:545 in Table 1. Amino acids conserved among all sequences
are indicted by a "*" and generally conserved amino acids are
indicated by a ":".
[0048] FIG. 34 depicts a sequence alignment between SEQ ID NO:562
(RAAC00352) and ref|NP.sub.--691707.1|, ref|YP.sub.--829756.1|,
ref|YP.sub.--947785.1|, ref|YP.sub.--001221402.1|, and
ref|YP.sub.--885435.1| (SEQ ID NOS:564-568, respectively), which
all have the function assigned to SEQ ID NO:562 in Table 1. Amino
acids conserved among all sequences are indicted by a "*" and
generally conserved amino acids are indicated by a ":".
[0049] FIG. 35 depicts a sequence alignment between SEQ ID NO:579
(RAAC04321) and gb|ABW71834.1|, ref|YP.sub.--055250.1|,
ref|YP.sub.--612035.1|, ref|YP.sub.--134751.1|, and
ref|ZP.sub.--01441442.1| (SEQ ID NOS:581-585, respectively), which
all have the function assigned to SEQ ID NO:579 in Table 1. Amino
acids conserved among all sequences are indicted by a "*" and
generally conserved amino acids are indicated by a ":".
[0050] FIG. 36 depicts a sequence alignment between SEQ ID NO:596
(RAAC04349) and ref|YP.sub.--917551.1|, ref|ZP.sub.--00631342.1|,
ref|YP.sub.--001259911.1|, ref|NP.sub.--105797.1|, and
ref|ZP.sub.--00998521.1 (SEQ ID NOS:598-602, respectively), which
all have the function assigned to SEQ ID NO:596 in Table 1. Amino
acids conserved among all sequences are indicted by a "*" and
generally conserved amino acids are indicated by a ":".
[0051] FIGS. 37A and 37B depict a sequence alignment between SEQ ID
NO:613 (RAAC01327) and emb|CAD30313.1|, ref|ZP.sub.--01697379.1|,
ref|YP.sub.--001375474.1|, ref|NP.sub.--833288.1|, and
ref|NP.sub.--979866.1| (SEQ ID NOS:615-619, respectively), which
all have the function assigned to SEQ ID NO:613 in Table 1. Amino
acids conserved among all sequences are indicted by a "*" and
generally conserved amino acids are indicated by a ":".
[0052] FIGS. 38A and 38B depict a sequence alignment between SEQ ID
NO:630 (RAAC01351) and ref|YP.sub.--001125497.1|,
ref|YP.sub.--175672.1|, ref|NP.sub.--243001.1|,
ref|YP.sub.--147384.1|, and ref|YP.sub.--001108459.1| (SEQ ID
NOS:632-636, respectively), which all have the function assigned to
SEQ ID NO:630 in Table 1. Amino acids conserved among all sequences
are indicted by a "*" and generally conserved amino acids are
indicated by a ":".
[0053] FIGS. 39A and 39B depict a sequence alignment between SEQ ID
NO:647 (RAAC01352) and ref|YP.sub.--147385.1|,
ref|YP.sub.--001125498.1|, ref|YP.sub.--175671.1|,
ref|NP.sub.--926015.1|, and ref|YP.sub.--001660274.1| (SEQ ID
NOS:649-653, respectively), which all have the function assigned to
SEQ ID NO:647 in Table 1. Amino acids conserved among all sequences
are indicted by a "*" and generally conserved amino acids are
indicated by a ":".
[0054] FIGS. 40A and 40B depict a sequence alignment between SEQ ID
NO:664 (RAAC01354) and ref|YP.sub.--001636557.1|,
ref|ZP.sub.--01517435.1|, ref|ZP.sub.--01697170.1|,
ref|YP.sub.--001374183.1|, and ref|YP.sub.--082630.1| (SEQ ID
NOS:666-670, respectively), which all have the function assigned to
SEQ ID NO:664 in Table 1. Amino acids conserved among all sequences
are indicted by a "*" and generally conserved amino acids are
indicated by a ":".
[0055] FIGS. 41A and 41B depict a sequence alignment between SEQ ID
NO:681 (RAAC01360) and ref|ZP.sub.--01724857.1|,
ref|ZP.sub.--00235684.1|, ref|YP.sub.--895924.1|,
ref|YP.sub.--037600.1|, and ref|YP.sub.--001646030.1| (SEQ ID
NOS:683-687, respectively), which all have the function assigned to
SEQ ID NO:681 in Table 1. Amino acids conserved among all sequences
are indicted by a "*" and generally conserved amino acids are
indicated by a ":".
[0056] FIG. 42 depicts a sequence alignment between SEQ ID NO:698
(RAAC01408) and ref|YP.sub.--872951.1|, gb|AAQ84159.1|,
ref|YP.sub.--701593.1|, ref|YP.sub.--885121.1|, and
ref|ZP.sub.--02169377.1| (SEQ ID NOS:700-704, respectively), which
all have the function assigned to SEQ ID NO:698 in Table 1. Amino
acids conserved among all sequences are indicted by a "*" and
generally conserved amino acids are indicated by a ":".
[0057] FIG. 43 depicts a sequence alignment between SEQ ID NO:715
(RAAC01425) and ref|YP.sub.--146050.1|, ref|YP.sub.--001124307.1|,
ref|YP.sub.--360564.1|, ref|NP.sub.--691609.1|, and
ref|NP.sub.--294646.1| (SEQ ID NOS:717-721, respectively), which
all have the function assigned to SEQ ID NO:715 in Table 1. Amino
acids conserved among all sequences are indicted by a "*" and
generally conserved amino acids are indicated by a ":".
[0058] FIG. 44 depicts a sequence alignment between SEQ ID NO:732
(RAAC01517) and ref|YP.sub.--902570.1|, ref|YP.sub.--076319.1|,
ref|YP.sub.--001629366.1|, ref|ZP.sub.--01667660.1|, and
ref|YP.sub.--429281.1| (SEQ ID NOS:734-738, respectively), which
all have the function assigned to SEQ ID NO:732 in Table 1. Amino
acids conserved among all sequences are indicted by a "*" and
generally conserved amino acids are indicated by a ":".
[0059] FIG. 45 depicts a sequence alignment between SEQ ID NO:749
(RAAC00449) and ref|ZP.sub.--01666747.1|, pdb|2QE7|H,
sp|P22480|ATPE_BACPF, ref|ZP.sub.--01188594.1|, and
ref|YP.sub.--521144.1| (SEQ ID NOS:751-755, respectively), which
all have the function assigned to SEQ ID NO:749 in Table 1. Amino
acids conserved among all sequences are indicted by a "*" and
generally conserved amino acids are indicated by a ":".
[0060] FIGS. 46A and 46B depict a sequence alignment between SEQ ID
NO:766 (RAAC01555) and ref|YP.sub.--079644.1|,
sp|P23630|DCDA_BACSU, ref|NP.sub.--390219.1|,
ref|YP.sub.--001421740.1|, and ref|YP.sub.--001487298.1| (SEQ ID
NOS:768-772, respectively), which all have the function assigned to
SEQ ID NO:766 in Table 1. Amino acids conserved among all sequences
are indicted by a "*" and generally conserved amino acids are
indicated by a ":".
[0061] FIGS. 47A and 47B depict a sequence alignment between SEQ ID
NO:783 (RAAC01575) and ref|NP.sub.--241871.1|,
ref|YP.sub.--077980.1|, ref|YP.sub.--001420375.1|,
ref|NP.sub.--388616.1|, and ref|NP.sub.--693628.1| (SEQ ID
NOS:785-789, respectively), which all have the function assigned to
SEQ ID NO:783 in Table 1. Amino acids conserved among all sequences
are indicted by a "*" and generally conserved amino acids are
indicated by a ":".
[0062] FIG. 48 depicts a sequence alignment between SEQ ID NO:800
(RAAC01657) and dbj|BAB40585.1|, ref|NP.sub.--241079.1|,
ref|YP.sub.--001126012.1|, ref|ZP01171269.1|, and
ref|ZP.sub.--01860561.1| (SEQ ID NOS:802-806, respectively), which
all have the function assigned to SEQ ID NO:800 in Table 1. Amino
acids conserved among all sequences are indicted by a "*" and
generally conserved amino acids are indicated by a ":".
[0063] FIG. 49 depicts a sequence alignment between SEQ ID NO:817
(RAAC01658) and ref|NP.sub.--241080.1|, dbj|BAB40586.1|,
ref|YP.sub.--001126011.1|, ref|NP.sub.--693798.1|, and
ref|ZP.sub.--00539126.1| (SEQ ID NOS:819-823, respectively), which
all have the function assigned to SEQ ID NO:817 in Table 1. Amino
acids conserved among all sequences are indicted by a "*" and
generally conserved amino acids are indicated by a ":".
[0064] FIG. 50 depicts a sequence alignment between SEQ ID NO:834
(RAAC01669) and ref|YP.sub.--001125402.1|, ref|YP.sub.--147282.1|,
ref|ZP.sub.--01859257.1|, ref|NP.sub.--388913.1|, and
ref|YP.sub.--001420249.1| (SEQ ID NOS:836-840, respectively), which
all have the function assigned to SEQ ID NO:834 in Table 1. Amino
acids conserved among all sequences are indicted by a "*" and
generally conserved amino acids are indicated by a ":".
[0065] FIGS. 51A-51C depict a sequence alignment between SEQ ID
NO:851 (RAAC01678) and ref|ZP.sub.--01696606.1|,
ref|YP.sub.--146312.1, ref|ZP.sub.--01171726.1,
ref|YP.sub.--001124591.1|, and ref|ZP.sub.--01696079.1| (SEQ ID
NOS:853-857, respectively), which all have the function assigned to
SEQ ID NO:851 in Table 1. Amino acids conserved among all sequences
are indicted by a "*" and generally conserved amino acids are
indicated by a ":".
[0066] FIGS. 52A and 52B depict a sequence alignment between SEQ ID
NO:868 (RAAC01685) and ref|YP.sub.--431081.1|,
ref|YP.sub.--001211085.1|, ref|YP.sub.--001111663.1|,
ref|YP.sub.--001547204.1|, and ref|NP.sub.--213242.1| (SEQ ID
NOS:870-874, respectively), which all have the function assigned to
SEQ ID NO:868 in Table 1. Amino acids conserved among all sequences
are indicted by a "*" and generally conserved amino acids are
indicated by a ":".
[0067] FIG. 53 depicts a sequence alignment between SEQ ID NO:885
(RAAC01745) and ref|YP.sub.--001127228.1|, ref|YP.sub.--149070.1|,
ref|ZP.sub.--00539127.1|, ref|NP.sub.--241079.1|, and
ref|YP.sub.--074240.1| (SEQ ID NOS:887-891, respectively), which
all have the function assigned to SEQ ID NO:885 in Table 1. Amino
acids conserved among all sequences are indicted by a "*" and
generally conserved amino acids are indicated by a ":".
[0068] FIG. 54 depicts a sequence alignment between SEQ ID NO:902
(RAAC01746) and ref|YP.sub.--149069.1|, ref|YP.sub.--001127227.1|,
ref|ZP.sub.--00539126.1|, ref|YP.sub.--001125046.1|, and
ref|NP.sub.--833691.1| (SEQ ID NOS:904-908, respectively), which
all have the function assigned to SEQ ID NO:902 in Table 1. Amino
acids conserved among all sequences are indicted by a "*" and
generally conserved amino acids are indicated by a ":".
[0069] FIG. 55 depicts a sequence alignment between SEQ ID NO:919
(RAAC01748) and ref|NP.sub.--828658.1|, emb|CAJ88521.1|,
ref|NP.sub.--625066.1|, ref|YP.sub.--001104836.1|, and
ref|YP.sub.--658557.1| (SEQ ID NOS:921-925, respectively), which
all have the function assigned to SEQ ID NO:919 in Table 1. Amino
acids conserved among all sequences are indicted by a "*" and
generally conserved amino acids are indicated by a ":".
[0070] FIGS. 56A and 56B depict a sequence alignment between SEQ ID
NO:936 (RAAC00450) and pdb|2QE7|D, sp|Q9LA80|ATPB_GEOTH,
ref|YP.sub.--149211.11, sp|P41009|ATPB_BACCA, and
prf.parallel.1211283A (SEQ ID NOS:938-942, respectively), which all
have the function assigned to SEQ ID NO:936 in Table 1. Amino acids
conserved among all sequences are indicted by a "*" and generally
conserved amino acids are indicated by a ":".
[0071] FIGS. 57A-57C depict a sequence alignment between SEQ 1D
NO:953 (RAAC01759) and ref|ZP.sub.--02170376.1|,
ref|YP.sub.--001546865.1|, ref|YP.sub.--001125323.1|,
ref|YP.sub.--147200.21, and ref|YP.sub.--091630.1 (SEQ ID
NOS:955-959, respectively), which all have the function assigned to
SEQ ID NO:953 in Table 1. Amino acids conserved among all sequences
are indicted by a "*" and generally conserved amino acids are
indicated by a ":".
[0072] FIG. 58 depicts a sequence alignment between SEQ ID NO:970
(RAAC01762) and gb|ABW71834.1|, ref|ZP.sub.--02015336.1|,
ref|YP.sub.--055250.1|, ref|YP.sub.--136548.1|, and
ref|NP.sub.--102793.1| (SEQ ID NOS:972-976, respectively), which
all have the function assigned to SEQ ID NO:970 in Table 1. Amino
acids conserved among all sequences are indicted by a "*" and
generally conserved amino acids are indicated by a ":".
[0073] FIG. 59 depicts a sequence alignment between SEQ ID NO:987
(RAAC01763) and ref|YP.sub.--300327.1|, ref|NP.sub.--693723.1|,
ref|YP.sub.--190012.1|, ref|YP.sub.--252288.1|, and
ref|ZP.sub.--01227084.1| (SEQ ID NOS:989-993, respectively), which
all have the function assigned to SEQ ID NO:987 in Table 1. Amino
acids conserved among all sequences are indicted by a "*" and
generally conserved amino acids are indicated by a ":".
[0074] FIG. 60 depicts a sequence alignment between SEQ ID NO:1004
(RAAC01767) and ref|ZP.sub.--01860323.1|, ref|NP.sub.--244450.1|,
ref|YP.sub.--148929.1|, ref|YP.sub.--080823.1|, and
ref|ZP.sub.--01171654.1| (SEQ ID NOS:1006-1010, respectively),
which all have the function assigned to SEQ ID NO:1004 in Table 1.
Amino acids conserved among all sequences are indicted by a "*" and
generally conserved amino acids are indicated by a ":".
[0075] FIG. 61 depicts a sequence alignment between SEQ ID NO:1021
(RAAC01797) and ref|YP.sub.--076186.1|, ref|NP.sub.--691214.1|,
ref|ZP.sub.--01170331.1|, ref|NP.sub.--388333.1|, and
ref|YP.sub.--001375327.1| (SEQ ID NOS:1023-1027, respectively),
which all have the function assigned to SEQ ID NO:1021 in Table 1.
Amino acids conserved among all sequences are indicted by a "*" and
generally conserved amino acids are indicated by a ":".
[0076] FIGS. 62A and 62B depict a sequence alignment between SEQ ID
NO:1038 (RAAC01900) and ref|NP.sub.--691405.1|,
ref|NP.sub.--242876.1|, ref|NP.sub.--241871.1|,
ref|YP.sub.--001420375.1|, and ref|NP.sub.--388616.1| (SEQ ID
NOS:1040-1044, respectively), which all have the function assigned
to SEQ ID NO:1038 in Table 1. Amino acids conserved among all
sequences are indicted by a "*" and generally conserved amino acids
are indicated by a ":".
[0077] FIG. 63 depicts a sequence alignment between SEQ ID NO:1055
(RAAC01939) and ref|NP.sub.--390790.1|, ref|ZP.sub.--02170616.1|,
ref|NP.sub.--693087.1|, ref|YP.sub.--080204.1|, and
sp|Q59202|MDH_BACIS (SEQ ID NOS:1057-1061, respectively), which all
have the function assigned to SEQ ID NO:1055 in Table 1. Amino
acids conserved among all sequences are indicted by a "*" and
generally conserved amino acids are indicated by a ":".
[0078] FIG. 64 depicts a sequence alignment between SEQ ID NO:1072
(RAAC01996) and ref|NP.sub.--244279.1|, ref|YP.sub.--001126997.1|,
ref|YP.sub.--148810.1|, ref|YP.sub.--001488092.1|, and
ref|NP.sub.--391097.1| (SEQ ID NOS:1074-1078, respectively), which
all have the function assigned to SEQ ID NO:1072 Table 1. Amino
acids conserved among all sequences are indicted by a "*" and
generally conserved amino acids are indicated by a ":".
[0079] FIG. 65 depicts a sequence alignment between SEQ ID NO:1089
(RAAC02025) and ref|NP.sub.--390723.1|, ref|YP.sub.--080139.1|,
ref|YP.sub.--001422141.1|, ref|ZP.sub.--01171785.1|, and
ref|NP.sub.--243959.1| (SEQ ID NOS:1091-1095, respectively), which
all have the function assigned to SEQ ID NO:1089 in Table 1. Amino
acids conserved among all sequences are indicted by a "*" and
generally conserved amino acids are indicated by a ":".
[0080] FIG. 66 depicts a sequence alignment between SEQ ID NO:1106
(RAAC00451) and pdb|2QE7|G, ref|YP.sub.--001127389.1|,
ref|YP.sub.--149212.1|, ref|YP.sub.--001488540.1|, and
emb|CAA30654.1|(SEQ ID NOS:1108-1112, respectively), which all have
the function assigned to SEQ ID NO:1106 in Table 1. Amino acids
conserved among all sequences are indicted by a "*" and generally
conserved amino acids are indicated by a ":".
[0081] FIGS. 67A and 67B depict a sequence alignment between SEQ ID
NO:1123 (RAAC02026) and ref|YP.sub.--148525.1|,
ref|YP.sub.--001126690.1|, emb|CAA69872.1|, ref|YP.sub.--092553.1|,
and ref|NP.sub.--243958.1|(SEQ ID NOS:1125-1129, respectively),
which all have the function assigned to SEQ ID NO:1123 in Table 1.
Amino acids conserved among all sequences are indicted by a "*" and
generally conserved amino acids are indicated by a ":".
[0082] FIG. 68 depicts a sequence alignment between SEQ ID NO:1140
(RAAC02027) and emb|CAA69873.1|, ref|YP.sub.--148524.1|,
ref|YP.sub.--080136.1|, ref|NP.sub.--243957.1|, and
ref|ZP.sub.--01697535.1 (SEQ ID NOS:1142-1146, respectively), which
all have the function assigned to SEQ ID NO:1140 in Table 1. Amino
acids conserved among all sequences are indicted by a "*" and
generally conserved amino acids are indicated by a ":".
[0083] FIG. 69 depicts a sequence alignment between SEQ ID NO:1157
(RAAC02040) and ref|ZP.sub.--01697399.1|,
ref|YP.sub.--001124579.1|, ref|YP.sub.--146298.1|,
ref|NP.sub.--691785.1|, and ref|ZP.sub.--01723229.1| (SEQ ID
NOS:1159-1163, respectively), which all have the function assigned
to SEQ ID NO:1157 in Table 1. Amino acids conserved among all
sequences are indicted by a "*" and generally conserved amino acids
are indicated by a ":".
[0084] FIGS. 70A and 70B depict a sequence alignment between SEQ ID
NO:1174 (RAAC02181) and ref|NP.sub.--391000.1|,
ref|YP.sub.--080655.1|, ref|YP.sub.--173878.1|,
ref|NP.sub.--242416.1|, and ref|YP.sub.--644452.1| (SEQ ID
NOS:1176-1180, respectively), which all have the function assigned
to SEQ ID NO:1174 in Table 1. Amino acids conserved among all
sequences are indicted by a "*" and generally conserved amino acids
are indicated by a ":".
[0085] FIG. 71 depicts a sequence alignment between SEQ ID NO:1191
(RAAC02222) and ref|YP.sub.--001487576.1|,
ref|ZP.sub.--02211990.1|, ref|YP.sub.--001343716.1|,
ref|NP.sub.--744947.1|, and ref|YP.sub.--633768.1| (SEQ ID
NOS:1193-1197, respectively), which all have the function assigned
to SEQ ID NO:1191 in Table 1. Amino acids conserved among all
sequences are indicted by a "*" and generally conserved amino acids
are indicated by a ":".
[0086] FIGS. 72A and 72B depict a sequence alignment between SEQ ID
NO:1208 (RAAC02274) and ref|YP.sub.--146053.1|,
ref|ZP.sub.--01869175.1|, ref|ZP.sub.--00989613.1|,
ref|YP.sub.--001276414.1|, and ref|YP.sub.--001211401.1| (SEQ ID
NOS:1210-1214, respectively), which all have the function assigned
to SEQ ID NO:1208 in Table 1. Amino acids conserved among all
sequences are indicted by a "*" and generally conserved amino acids
are indicated by a ":".
[0087] FIGS. 73A and 73B depict a sequence alignment between SEQ ID
NO:1225 (RAAC02275) and ref|YP.sub.--146052.1|,
ref|YP.sub.--001546552.1|, ref|YP.sub.--001636911.1|,
ref|ZP.sub.--01514632.1|, and ref|YP.sub.--001274650.1| (SEQ ID
NOS:1227-1231, respectively), which all have the function assigned
to SEQ ID NO:1225 in Table 1. Amino acids conserved among all
sequences are indicted by a "*" and generally conserved amino acids
are indicated by a ":".
[0088] FIG. 74 depicts a sequence alignment between SEQ ID NO:1242
(RAAC02426) and ref|NP.sub.--243521.1|, pdb|1W85|A,
sp|P21873|ODPA_BACST, ref|YP.sub.--001421036.1|, and
ref|YP.sub.--146911.1| (SEQ ID NOS:1244-1248, respectively), which
all have the function assigned to SEQ ID NO:1242 in Table 1. Amino
acids conserved among all sequences are indicted by a "*" and
generally conserved amino acids are indicated by a ":".
[0089] FIG. 75 depicts a sequence alignment between SEQ ID NO:1259
(RAAC02427) and ref|ZP.sub.--01696304.1|, sp|P21874|ODPB_BACST,
ref|YP.sub.--001125046.1|, pdb|1W85|B, and ref|YP.sub.--146912.1|
(SEQ ID NOS:1261-1265, respectively), which all have the function
assigned to SEQ ID NO:1259 Table 1. Amino acids conserved among all
sequences are indicted by a "*" and generally conserved amino acids
are indicated by a ":".
[0090] FIGS. 76A and 76B depict a sequence alignment between SEQ ID
NO:1276 (RAAC02429) and ref|YP.sub.--001125048.1|,
sp|P11959|DLDH1_BACST, ref|YP.sub.--146914.1|,
ref|YP.sub.--001486601.1|, and pdb|1EBD|A (SEQ ID NOS:1278-1282,
respectively), which all have the function assigned to SEQ ID
NO:1276 in Table 1. Amino acids conserved among all sequences are
indicted by a "*" and generally conserved amino acids are indicated
by a ":".
[0091] FIGS. 77A and 77B depicts a sequence alignment between SEQ
ID NO:1293 (RAAC00452) and pdb|2QE7|A, ref|YP.sub.--361340.1|,
ref|YP.sub.--001127390.1|, ref|YP.sub.--149213.1|, and
ref|YP.sub.--001356688.1| (SEQ ID NOS:1295-1299, respectively),
which all have the function assigned to SEQ ID NO:1293 in Table 1.
Amino acids conserved among all sequences are indicted by a "*" and
generally conserved amino acids are indicated by a ":".
[0092] FIG. 78 depicts a sequence alignment between SEQ ID NO:1310
(RAAC02433) and ref|YP.sub.--001542913.1|, ref|YP.sub.--644829.1|,
ref|YP.sub.--356005.1|, emb|CAO90974.1|, and
ref|YP.sub.--001656571.1| (SEQ ID NOS:1312-1316, respectively),
which all have the function assigned to SEQ ID NO:1310 in Table 1.
Amino acids conserved among all sequences are indicted by a "*" and
generally conserved amino acids are indicated by a ":".
[0093] FIGS. 79A and 79B depict a sequence alignment between SEQ ID
NO:1327 (RAAC02438) and ref|YP.sub.--644476.1|,
ref|ZP.sub.--02191297.1|, ref|ZP.sub.--01549387.1|,
ref|ZP.sub.--01850519.1|, and ref|ZP.sub.--01015586.1| (SEQ ID
NOS:1329-1333, respectively), which all have the function assigned
to SEQ ID NO:1327 in Table 1. Amino acids conserved among all
sequences are indicted by a "*" and generally conserved amino acids
are indicated by a ":".
[0094] FIGS. 80A and 80B depict a sequence alignment between SEQ ID
NO:1344 (RAAC02441) and ref|YP.sub.--147804.1|,
ref|YP.sub.--001125954.1|, ref|YP.sub.--001125911.1|,
ref|YP.sub.--147740.1|, and ref|NP.sub.--243178.1| (SEQ ID
NOS:1346-1350, respectively), which all have the function assigned
to SEQ ID NO:1344 in Table 1. Amino acids conserved among all
sequences are indicted by a "*" and generally conserved amino acids
are indicated by a ":".
[0095] FIG. 81 depicts a sequence alignment between SEQ ID NO:1361
(RAAC02442) and ref|YP.sub.--001125956.1|, ref|YP.sub.--147805.1|,
ref|ZP.sub.--01169177.1, ref|ZP.sub.--01695873.1|, and
ref|NP.sub.--831941.1| (SEQ ID NOS:1363-1367, respectively), which
all have the function assigned to SEQ ID NO:1361 in Table 1. Amino
acids conserved among all sequences are indicted by a "*" and
generally conserved amino acids are indicated by a ":".
[0096] FIGS. 82A and 82B depict a sequence alignment between SEQ ID
NO:1378 (RAAC02630) and ref|ZP.sub.--01695367.1|,
ref|YP.sub.--723673.1|, ref|YP.sub.--686117.1|,
ref|YP.sub.--001111391.1|, and ref|ZP.sub.--01623360.1| (SEQ ID
NOS:1380-1384, respectively), which all have the function assigned
to SEQ ID NO:1378 in Table 1. Amino acids conserved among all
sequences are indicted by a "*" and generally conserved amino acids
are indicated by a ":".
[0097] FIG. 83 depicts a sequence alignment between SEQ ID NO:1395
(RAAC02644) and ref|NP.sub.--782567.1|, sp|Q892U0|LDH_CLOTE,
ref|YP.sub.--590559.1|, ref|ZP.sub.--01514103.1|, and
ref|YP.sub.--009822.1| (SEQ ID NOS:1397-1401, respectively), which
all have the function assigned to SEQ ID NO:1395 in Table 1. Amino
acids conserved among all sequences are indicted by a "*" and
generally conserved amino acids are indicated by a ":".
[0098] FIGS. 84A and 84B depict a sequence alignment between SEQ ID
NO:1412 (RAAC02702) and ref|YP.sub.--001124710.1|,
ref|YP.sub.--146529.1|, ref|NP.sub.--977551.1|,
ref|YP.sub.--893868.1|, and ref|NP.sub.--843617.1| (SEQ ID
NOS:1414-1418, respectively), which all have the function assigned
to SEQ ID NO:1412 in Table 1. Amino acids conserved among all
sequences are indicted by a "*" and generally conserved amino acids
are indicated by a ":".
[0099] FIGS. 85A and 85B depict a sequence alignment between SEQ ID
NO:1429 (RAAC04058) and ref|ZP.sub.--02080303.1|,
ref|YP.sub.--520543.1|, ref|ZP.sub.--01966380.1|,
ref|ZP.sub.--02039587.1|, and ref|ZP.sub.--02073747.1| (SEQ ID
NOS:1431-1435, respectively), which all have the function assigned
to SEQ ID NO:1429 in Table 1. Amino acids conserved among all
sequences are indicted by a "*" and generally conserved amino acids
are indicated by a ":".
[0100] FIGS. 86A and 86B depict a sequence alignment between SEQ ID
NO:1446 (RAAC02843) and ref|YP.sub.--001125182.1|,
ref|YP.sub.--147061.1|, ref|ZP.sub.--01171540.1|,
ref|NP.sub.--692464.1|, and ref|YP.sub.--001375719.1| (SEQ ID
NOS:1448-1452, respectively), which all have the function assigned
to SEQ ID NO:1446 in Table 1. Amino acids conserved among all
sequences are indicted by a "*" and generally conserved amino acids
are indicated by a ":".
[0101] FIG. 87 depicts a sequence alignment between SEQ ID NO:1463
(RAAC02844) and ref|YP.sub.--147062.1, ref|YP.sub.--001125183.1|,
ref|YP.sub.--079003.1, ref|NP.sub.--243335.1|, and
ref|ZP.sub.--01171539.1| (SEQ ID NOS:1465-1469, respectively),
which all have the function assigned to SEQ ID NO:1463 in Table 1.
Amino acids conserved among all sequences are indicted by a "*" and
generally conserved amino acids are indicated by a ":".
[0102] FIG. 88 depicts a sequence alignment between SEQ ID NO:1480
(RAAC00454) and ref|YP.sub.--001127392.1|, ref|YP.sub.--521149.1|,
ref|YP.sub.--149215.1|, ref|YP.sub.--001488543.1|, and
ref|YP.sub.--093437.1| (SEQ ID NOS:1482-1486, respectively), which
all have the function assigned to SEQ ID NO:1480 in Table 1. Amino
acids conserved among all sequences are indicted by a "*" and
generally conserved amino acids are indicated by a ":".
[0103] FIG. 89 depicts a sequence alignment between SEQ ID NO:1497
(RAAC02920) and ref|YP.sub.--001421255.1|, ref|NP.sub.--389559.1|,
ref|YP.sub.--001125250.1|, ref|ZP.sub.--02169638.1|, and
ref|YP.sub.--091490.1| (SEQ ID NOS:1499-1503, respectively), which
all have the function assigned to SEQ ID NO:1497 in Table 1. Amino
acids conserved among all sequences are indicted by a "*" and
generally conserved amino acids are indicated by a ":".
[0104] FIGS. 90A and 90B depict a sequence alignment between SEQ ID
NO:1514 (RAAC02924) and ref|YP.sub.--001375026.1|,
ref|YP.sub.--175305.1|, ref|NP.sub.--844736.1|,
ref|NP.sub.--691737.1|, and ref|NP.sub.--832053.1| (SEQ ID
NOS:1516-1520, respectively), which all have the function assigned
to SEQ ID NO:1514 in Table 1. Amino acids conserved among all
sequences are indicted by a "*" and generally conserved amino acids
are indicated by a ":".
[0105] FIGS. 91A and 91B depict a sequence alignment between SEQ ID
NO:1531 (RAAC02926) and ref|YP.sub.--148646.1|,
ref|ZP.sub.--01696063.1|, ref|ZP.sub.--01859600.1|,
ref|YP.sub.--001376529.1|, and ref|YP.sub.--038694.1| (SEQ ID
NOS:1533-1537, respectively), which all have the function assigned
to SEQ ID NO:1531 in Table 1. Amino acids conserved among all
sequences are indicted by a "*" and generally conserved amino acids
are indicated by a ":".
[0106] FIGS. 92A and 92B depict a sequence alignment between SEQ ID
NO:1548 (RAAC02986) and ref|YP.sub.--146227.1|,
ref|YP.sub.--001124476.1|, ref|ZP.sub.--01695767.1|,
dbj|BAB39706.1|, and ref|ZP.sub.--01723231.1| (SEQ ID
NOS:1550-1554, respectively), which all have the function assigned
to SEQ ID NO:1548 in Table 1. Amino acids conserved among all
sequences are indicted by a "*" and generally conserved amino acids
are indicated by a ":".
[0107] FIG. 93 depicts a sequence alignment between SEQ ID NO:1565
(RAAC03010) and ref|YP.sub.--001127080.1|, ref|YP.sub.--148885.1|,
ref|YP.sub.--001374290.1|. ref|NP.sub.--693789.1|, and
ref|YP.sub.--144223.1| (SEQ ID NOS:1567-1571, respectively), which
all have the function assigned to SEQ ID NO:1565 in Table 1. Amino
acids conserved among all sequences are indicted by a "*" and
generally conserved amino acids are indicated by a ":".
DETAILED DESCRIPTION OF THE INVENTION
[0108] Embodiments of the invention include genes and associated
proteins related to the metabolism of the thermoacidophile
Alicyclobacillus acidocaldarius. Coding sequences for genes related
to these processes were determined from sequence information
generated from sequencing the genome of Alicyclobacillus
acidocaldarius. These genes and proteins may represent targets
and/or elements of transformation systems or vectors for metabolic
engineering of Alicyclobacillus acidocaldarius or other organisms.
Non-limiting examples of nucleotide sequences found within the
genome of Alicyclobacillus acidocaldarius, and amino acids coded
thereby, associated with metabolism are listed in Table 1.
Metabolism proteins may be, without limitation, of the following
classes: (S)-2-hydroxy-acid oxidases, [acyl-carrier-protein]
S-malonyltransferases, 1,3-propanediol Dehydrogenases,
2-isopropylmalate Synthases, 3-hydroxybutyryl-CoA dehydratases,
3-isopropylmalate Dehydratases, 3-isopropylmalate Dehydrogenases,
3-oxoacid CoA-transferases, 8-amino-7-oxononanoate Synthases,
Acetaldehyde dehydrogenases (acetylating), Acetate-CoA ligases,
Acetolactate synthases, Acetyl-CoA C-acetyltransferases, Aconitate
hydratases, Alcohol dehydrogenases, Alcohol dehydrogenases (NADP+),
Aldehyde dehydrogenases, Aldehyde dehydrogenases (NAD+), ATP
phosphoribosyltransferases, ATP synthase alpha chains, ATP synthase
B chains, ATP synthase beta chains, ATP synthase C chains, ATP
synthase epsilon chains, ATP synthase gamma chains, Biotin
synthases, Branched-chain-amino-acid transaminases, Butyryl-CoA
dehydrogenases, Citrate (Si)-synthases, Dethiobiotin synthases,
Diaminopimelate decarboxylases, Diaminopimelate epimerases,
Dihydrodipicolinate reductases, Dihydrodipicolinate synthases,
Dihydrolipoyl dehydrogenases, Dihydroxy-acid dehydratases,
Enoyl-CoA hydratases, FdhD proteins (fdsC), Formate dehydrogenases,
Glycerate kinases, Glycine hydroxymethyltransferases, Isocitrate
lyases, Lactaldehyde reductases, Lactate 2-monooxygenases,
L-lactate dehydrogenases, Malate dehydrogenases, Malate
dehydrogenases (acceptor), Malate dehydrogenases
(oxaloacetate-decarboxylating), Malate synthases,
Malonate-semialdehyde dehydrogenases (acetylating),
Methylmalonate-semialdehyde dehydrogenases (acylating),
N-acetyldiaminopimelate deacetylases, Oxoglutarate dehydrogenases
(succinyl-transferring), Phosphoenolpyruvate carboxylases,
Phosphoglycerate dehydrogenases, Phosphoribosylanthranilate
isomerases, Pyruvate dehydrogenases (acetyl-transferring), Pyruvate
phosphate dikinases, Succinate dehydrogenase cytochrome b558
subunits, Succinate dehydrogenase flavoprotein subunits, Succinate
dehydrogenase iron-sulfur proteins, Succinate-CoA ligases
(ADP-forming); and others.
[0109] Embodiments of the invention relate in part to the gene
sequences and/or protein sequences comprising genes and/or proteins
of Alicyclobacillus acidocaldarius. Genes and proteins included are
those that play a role in metabolism. Intracellular enzyme
activities may be thermophilic and/or acidophilic in nature and
general examples of similar genes are described in the literature.
Classes of genes, sequences, enzymes and factors include, but are
not limited to, those listed in Table 1.
TABLE-US-00001 TABLE 1 Alicyclobacillus acidocaldarius genes
related to metabolism Reference Gene Sequence Protein Sequence
Function RAAC00079 SEQ ID NO: 1 SEQ ID NO: 2 Acetate-CoA ligase
RAAC00455 SEQ ID NO: 18 SEQ ID NO: 19 ATP synthase C chain
RAAC00461 SEQ ID NO: 35 SEQ ID NO: 36 Glycine
hydroxymethyltransferase RAAC00481 SEQ ID NO: 52 SEQ ID NO: 53
3-hydroxybutyryl-CoA dehydratase RAAC00529 SEQ ID NO: 69 SEQ ID NO:
70 N-acetyldiaminopimelate deacetylase RAAC00552 SEQ ID NO: 86 SEQ
ID NO: 87 Biotin synthase RAAC00553 SEQ ID NO: 103 SEQ ID NO: 104
Dethiobiotin synthase RAAC00554 SEQ ID NO: 120 SEQ ID NO: 121
8-amino-7-oxononanoate Synthase RAAC00632 SEQ ID NO: 137 SEQ ID NO:
138 Branched-chain-amino-acid transaminase RAAC00633 SEQ ID NO: 154
SEQ ID NO: 155 Dihydroxy-acid dehydratase RAAC00634 SEQ ID NO: 171
SEQ ID NO: 172 Acetolactate synthase RAAC00174 SEQ ID NO: 188 SEQ
ID NO: 189 [acyl-carrier-protein] S-malonyltransferase RAAC00635
SEQ ID NO: 205 SEQ ID NO: 206 Acetolactate synthase RAAC00637 SEQ
ID NO: 222 SEQ ID NO: 223 3-isopropylmalate Dehydrogenase RAAC00638
SEQ ID NO: 239 SEQ ID NO: 240 3-isopropylmalate Dehydratase
RAAC00639 SEQ ID NO: 256 SEQ ID NO: 257 3-isopropylmalate
Dehydratase RAAC00642 SEQ ID NO: 273 SEQ ID NO: 274 Citrate
(Si)-synthase RAAC00727 SEQ ID NO: 290 SEQ ID NO: 291 Oxoglutarate
dehydrogenase (succinyl-transferring) RAAC00729 SEQ ID NO: 307 SEQ
ID NO: 308 Malate dehydrogenase (acceptor) RAAC00730 SEQ ID NO: 324
SEQ ID NO: 325 Malate dehydrogenase (oxaloacetate-decarboxylating)
RAAC00735 SEQ ID NO: 341 SEQ ID NO: 342 Phosphoenolpyruvate
carboxylase RAAC00812 SEQ ID NO: 358 SEQ ID NO: 359 3-oxoacid
CoA-transferase RAAC00196 SEQ ID NO: 375 SEQ ID NO: 376 Malate
dehydrogenase (oxaloacetate-decarboxylating) RAAC00814 SEQ ID NO:
392 SEQ ID NO: 393 Acetyl-CoA C-acetyltransferase RAAC00815 SEQ ID
NO: 409 SEQ ID NO: 410 Acetate-CoA ligase RAAC00816 SEQ ID NO: 426
SEQ ID NO: 427 Butyryl-CoA dehydrogenase RAAC00822 SEQ ID NO: 443
SEQ ID NO: 444 3-hydroxybutyryl-CoA dehydratase RAAC00950 SEQ ID
NO: 460 SEQ ID NO: 461 Formate dehydrogenase RAAC00952 SEQ ID NO:
477 SEQ ID NO: 478 FdhD protein (fdsC) RAAC00990 SEQ ID NO: 494 SEQ
ID NO: 495 Dihydrodipicolinate reductase RAAC01029 SEQ ID NO: 511
SEQ ID NO: 512 Acetaldehyde dehydrogenase (acetylating) RAAC01041
SEQ ID NO: 528 SEQ ID NO: 529 Pyruvate, phosphate dikinase
RAAC01057 SEQ ID NO: 545 SEQ ID NO: 546 Enoyl-CoA hydratase
RAAC00352 SEQ ID NO: 562 SEQ ID NO: 563 Alcohol dehydrogenase
(NADP+) RAAC04321 SEQ ID NO: 579 SEQ ID NO: 580 Alcohol
dehydrogenase RAAC04349 SEQ ID NO: 596 SEQ ID NO: 597
Phosphoribosylanthranilate isomerase RAAC01327 SEQ ID NO: 613 SEQ
ID NO: 614 Aldehyde dehydrogenase (NAD+) RAAC01351 SEQ ID NO: 630
SEQ ID NO: 631 (S)-2-hydroxy-acid oxidase RAAC01352 SEQ ID NO: 647
SEQ ID NO: 648 (S)-2-hydroxy-acid oxidase RAAC01354 SEQ ID NO: 664
SEQ ID NO: 665 Malate synthase RAAC01360 SEQ ID NO: 681 SEQ ID NO:
682 (S)-2-hydroxy-acid oxidase RAAC01408 SEQ ID NO: 698 SEQ ID NO:
699 Butyryl-CoA dehydrogenase RAAC01425 SEQ ID NO: 715 SEQ ID NO:
716 Butyryl-CoA dehydrogenase RAAC01517 SEQ ID NO: 732 SEQ ID NO:
733 Glycerate kinase RAAC00449 SEQ ID NO: 749 SEQ ID NO: 750 ATP
synthase epsilon chain RAAC01555 SEQ ID NO: 766 SEQ ID NO: 767
Diaminopimelate decarboxylase RAAC01575 SEQ ID NO: 783 SEQ ID NO:
784 Aldehyde dehydrogenase (NAD+) RAAC01657 SEQ ID NO: 800 SEQ ID
NO: 801 Pyruvate dehydrogenase (acetyl-transferring) RAAC01658 SEQ
ID NO: 817 SEQ ID NO: 818 Pyruvate dehydrogenase
(acetyl-transferring) RAAC01669 SEQ ID NO: 834 SEQ ID NO: 835
Alcohol dehydrogenase RAAC01678 SEQ ID NO: 851 SEQ ID NO: 852
Formate dehydrogenase RAAC01685 SEQ ID NO: 868 SEQ ID NO: 869
2-isopropylmalate Synthase RAAC01745 SEQ ID NO: 885 SEQ ID NO: 886
Pyruvate dehydrogenase (acetyl-transferring) RAAC01746 SEQ ID NO:
902 SEQ ID NO: 903 Pyruvate dehydrogenase (acetyl-transferring)
RAAC01748 SEQ ID NO: 919 SEQ ID NO: 920 Lactate 2-monooxygenase
RAAC00450 SEQ ID NO: 936 SEQ ID NO: 937 ATP synthase beta chain
RAAC01759 SEQ ID NO: 953 SEQ ID NO: 954 Aconitate hydratase
RAAC01762 SEQ ID NO: 970 SEQ ID NO: 971 Alcohol dehydrogenase
RAAC01763 SEQ ID NO: 987 SEQ ID NO: 988 Alcohol dehydrogenase
RAAC01767 SEQ ID NO: 1004 SEQ ID NO: 1005 ATP
phosphoribosyltransferase RAAC01797 SEQ ID NO: 1021 SEQ ID NO: 1022
Butyryl-CoA dehydrogenase RAAC01900 SEQ ID NO: 1038 SEQ ID NO: 1039
Aldehyde dehydrogenase RAAC01939 SEQ ID NO: 1055 SEQ ID NO: 1056
Malate dehydrogenase RAAC01996 SEQ ID NO: 1072 SEQ ID NO: 1073
Diaminopimelate epimerase RAAC02025 SEQ ID NO: 1089 SEQ ID NO: 1090
Succinate dehydrogenase cytochrome b558 subunit RAAC00451 SEQ ID
NO: 1106 SEQ ID NO: 1107 ATP synthase gamma chain RAAC02026 SEQ ID
NO: 1123 SEQ ID NO: 1124 Succinate dehydrogenase flavoprotein
subunit RAAC02027 SEQ ID NO: 1140 SEQ ID NO: 1141 Succinate
dehydrogenase iron-sulfur protein RAAC02040 SEQ ID NO: 1157 SEQ ID
NO: 1158 Butyryl-CoA dehydrogenase RAAC02181 SEQ ID NO: 1174 SEQ ID
NO: 1175 Lactaldehyde reductase RAAC02222 SEQ ID NO: 1191 SEQ ID
NO: 1192 1,3-propanediol Dehydrogenase RAAC02274 SEQ ID NO: 1208
SEQ ID NO: 1209 Alcohol dehydrogenase RAAC02275 SEQ ID NO: 1225 SEQ
ID NO: 1226 Aldehyde dehydrogenase (NAD+) RAAC02426 SEQ ID NO: 1242
SEQ ID NO: 1243 Pyruvate dehydrogenase (acetyl-transferring)
RAAC02427 SEQ ID NO: 1259 SEQ ID NO: 1260 Pyruvate dehydrogenase
(acetyl-transferring) RAAC02429 SEQ ID NO: 1276 SEQ ID NO: 1277
Dihydrolipoyl dehydrogenase RAAC00452 SEQ ID NO: 1293 SEQ ID NO:
1294 ATP synthase alpha chain RAAC02433 SEQ ID NO: 1310 SEQ ID NO:
1311 3-isopropylmalate Dehydrogenase RAAC02438 SEQ ID NO: 1327 SEQ
ID NO: 1328 Acetate-CoA ligase RAAC02441 SEQ ID NO: 1344 SEQ ID NO:
1345 Malonate-semialdehyde dehydrogenase (acetylating) RAAC02442
SEQ ID NO: 1361 SEQ ID NO: 1362 1,3-propanediol Dehydrogenase
RAAC02630 SEQ ID NO: 1378 SEQ ID NO: 1379 Phosphoglycerate
dehydrogenase RAAC02644 SEQ ID NO: 1395 SEQ ID NO: 1396 L-lactate
dehydrogenase RAAC02702 SEQ ID NO: 1412 SEQ ID NO: 1413 Isocitrate
lyase RAAC04058 SEQ ID NO: 1429 SEQ ID NO: 1430 2-isopropylmalate
Synthase RAAC02843 SEQ ID NO: 1446 SEQ ID NO: 1447 Succinate-CoA
ligase (ADP-forming) RAAC02844 SEQ ID NO: 1463 SEQ ID NO: 1464
Succinate-CoA ligase (ADP-forming) RAAC00454 SEQ ID NO: 1480 SEQ ID
NO: 1481 ATP synthase B chain RAAC02920 SEQ ID NO: 1497 SEQ ID NO:
1498 Dihydrodipicolinate synthase RAAC02924 SEQ ID NO: 1514 SEQ ID
NO: 1515 Methylmalonate-semialdehyde dehydrogenase (acylating)
RAAC02926 SEQ ID NO: 1531 SEQ ID NO: 1532 Acetate-CoA ligase
RAAC02986 SEQ ID NO: 1548 SEQ ID NO: 1549 Aldehyde dehydrogenase
(NAD+) RAAC03010 SEQ ID NO: 1565 SEQ ID NO: 1566
Dihydrodipicolinate synthase
[0110] The present invention relates to nucleotides sequences
comprising isolated and/or purified nucleotide sequences of the
genome of Alicyclobacillus acidocaldarius selected from the
sequences of SEQ ID NOS:2, 19, 36, 53, 70, 87, 104, 121, 138, 155,
172, 189, 206, 223, 240, 257, 274, 291, 308, 325, 342, 359, 376,
393, 410, 427, 444, 461, 478, 495, 512, 529, 546, 563, 580, 597,
614, 631, 648, 665, 682, 699, 716, 733, 750, 767, 784, 801, 818,
835, 852, 869, 886, 903, 920, 937, 954, 971, 988, 1005, 1022, 1039,
1056, 1073, 1090, 1107, 1124, 1141, 1158, 1175, 1192, 1209, 1226,
1243, 1260, 1277, 1294, 1311, 1328, 1345, 1362, 1379, 1396, 1413,
1430, 1447, 1464, 1481, 1498, 1515, 1532, 1549, and 1566 or one of
their fragments.
[0111] The present invention likewise relates to isolated and/or
purified nucleotide sequences, characterized in that they comprise
at least one of: a) a nucleotide sequence of at least one of the
sequences of SEQ ID NOS:2, 19, 36, 53, 70, 87, 104, 121, 138, 155,
172, 189, 206, 223, 240, 257, 274, 291, 308, 325, 342, 359, 376,
393, 410, 427, 444, 461, 478, 495, 512, 529, 546, 563, 580, 597,
614, 631, 648, 665, 682, 699, 716, 733, 750, 767, 784, 801, 818,
835, 852, 869, 886, 903, 920, 937, 954, 971, 988, 1005, 1022, 1039,
1056, 1073, 1090, 1107, 1124, 1141, 1158, 1175, 1192, 1209, 1226,
1243, 1260, 1277, 1294, 1311, 1328, 1345, 1362, 1379, 1396, 1413,
1430, 1447, 1464, 1481, 1498, 1515, 1532, 1549, and 1566 or one of
their fragments; b) a nucleotide sequence homologous to a
nucleotide sequence such as defined in a); c) a nucleotide sequence
complementary to a nucleotide sequence such as defined in a) or b),
and a nucleotide sequence of their corresponding RNA; d) a
nucleotide sequence capable of hybridizing under stringent
conditions with a sequence such as defined in a), b) or c); e) a
nucleotide sequence comprising a sequence such as defined in a),
b), c) or d); and f) a nucleotide sequence modified by a nucleotide
sequence such as defined in a), b), c), d) or e).
[0112] Nucleotide, polynucleotide, or nucleic acid sequence will be
understood according to the present invention as meaning both a
double-stranded or single-stranded DNA in the monomeric and dimeric
(so-called in tandem) forms and the transcription products of the
DNAs.
[0113] Aspects of the invention relate to nucleotide sequences in
which it has been possible to isolate, purify or partially purify,
starting from separation methods such as, for example, ion-exchange
chromatography, by exclusion based on molecular size, or by
affinity, or, alternatively, fractionation techniques based on
solubility in different solvents, or starting from methods of
genetic engineering such as amplification, cloning, and subcloning,
it being possible for the sequences of the invention to be carried
by vectors.
[0114] Isolated and/or purified nucleotide sequence fragment
according to the invention will be understood as designating any
nucleotide fragment of the genome of Alicyclobacillus
acidocaldarius, and may include, by way of non-limiting example, a
length of at least 8, 12, 20 25, 50, 75, 100, 200, 300, 400, 500,
1000, or more, consecutive nucleotides of the sequence from which
it originates.
[0115] Specific fragment of an isolated and/or purified nucleotide
sequence according to the invention will be understood as
designating any nucleotide fragment of the genome of
Alicyclobacillus acidocaldarius, having, after alignment and
comparison with the corresponding fragments of genomic sequences of
Alicyclobacillus acidocaldarius, at least one nucleotide or base of
different nature.
[0116] Homologous isolated and/or purified nucleotide sequence in
the sense of the present invention is understood as meaning an
isolated and/or purified nucleotide sequence having at least a
percentage identity with the bases of a nucleotide sequence
according to the invention of at least about 80%, 81%, 82%, 83%,
84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%,
97%, 98%, 99%, 99.5%, 99.6%, or 99.7%, this percentage being purely
statistical and it being possible to distribute the differences
between the two nucleotide sequences at random and over the whole
of their length.
[0117] Specific homologous nucleotide sequence in the sense of the
present invention is understood as meaning a homologous nucleotide
sequence having at least one nucleotide sequence of a specific
fragment, such as defined above. The "specific" homologous
sequences can comprise, for example, the sequences corresponding to
the genomic sequence or to the sequences of its fragments
representative of variants of the genome of Alicyclobacillus
acidocaldarius. These specific homologous sequences can thus
correspond to variations linked to mutations within strains of
Alicyclobacillus acidocaldarius, and especially correspond to
truncations, substitutions, deletions and/or additions of at least
one nucleotide. The homologous sequences can likewise correspond to
variations linked to the degeneracy of the genetic code.
[0118] The term "degree or percentage of sequence homology" refers
to "degree or percentage of sequence identity between two sequences
after optimal alignment" as defined in the present application.
[0119] Two amino-acids or nucleotidic sequences are said to be
"identical" if the sequence of amino-acids or nucleotidic residues,
in the two sequences is the same when aligned for maximum
correspondence as described below. Sequence comparisons between two
(or more) peptides or polynucleotides are typically performed by
comparing sequences of two optimally aligned sequences over a
segment or "comparison window" to identify and compare local
regions of sequence similarity. Optimal alignment of sequences for
comparison may be conducted by the local homology algorithm of
Smith and Waterman, Ad. App. Math 2:482 (1981), by the homology
alignment algorithm of Neddleman and Wunsch, J Mol. Biol. 48:443
(1970), by the search for similarity method of Pearson and Lipman,
Proc. Natl. Acad. Sci. (U.S.A.) 85:2444 (1988), by computerized
implementation of these algorithms (GAP, BESTFIT, FASTA, and TFASTA
in the Wisconsin Genetics Software Package, Genetics Computer Group
(GCG), 575 Science Dr., Madison, Wis.), or by visual
inspection.
[0120] "Percentage of sequence identity" (or degree of identity) is
determined by comparing two optimally aligned sequences over a
comparison window, where the portion of the peptide or
polynucleotide sequence in the comparison window may comprise
additions or deletions (i.e., gaps) as compared to the reference
sequence (which does not comprise additions or deletions) for
optimal alignment of the two sequences. The percentage is
calculated by determining the number of positions at which the
identical amino-acid residue or nucleic acid base occurs in both
sequences to yield the number of matched positions, dividing the
number of matched positions by the total number of positions in the
window of comparison and multiplying the result by 100 to yield the
percentage of sequence identity.
[0121] The definition of sequence identity given above is the
definition that would be used by one of skill in the art. The
definition by itself does not need the help of any algorithm, the
algorithms being helpful only to achieve the optimal alignments of
sequences, rather than the calculation of sequence identity.
[0122] From the definition given above, it follows that there is a
well-defined and only one value for the sequence identity between
two compared sequences, which value corresponds to the value
obtained for the best or optimal alignment.
[0123] In the BLAST N or BLAST P "BLAST 2 sequence," software,
which is available at the website ncbi.nlm.nih.gov/gorf/b12.html,
and habitually used by the inventors and in general by the skilled
person for comparing and determining the identity between two
sequences, gap cost, which depends on the sequence length to be
compared, is directly selected by the software (i.e., 11.2 for
substitution matrix BLOSUM-62 for length>85).
[0124] Complementary nucleotide sequence of a sequence of the
invention is understood as meaning any DNA whose nucleotides are
complementary to those of the sequence of the invention, and whose
orientation is reversed (antisense sequence).
[0125] Hybridization under conditions of stringency with a
nucleotide sequence according to the invention is understood as
meaning hybridization under conditions of temperature and ionic
strength chosen in such a way that they allow the maintenance of
the hybridization between two fragments of complementary DNA.
[0126] By way of illustration, conditions of great stringency of
the hybridization step with the aim of defining the nucleotide
fragments described above are advantageously the following.
[0127] The hybridization is carried out at a preferential
temperature of 65.degree. C. in the presence of SSC buffer,
1.times.SSC corresponding to 0.15 M NaCl and 0.05 M Na citrate. The
washing steps, for example, can be the following: 2.times.SSC, at
ambient temperature followed by two washes with 2.times.SSC, 0.5%
SDS at 65.degree. C.; 2.times.0.5.times.SSC, 0.5% SDS; at
65.degree. C. for 10 minutes each.
[0128] The conditions of intermediate stringency, using, for
example, a temperature of 42.degree. C. in the presence of a
2.times.SSC buffer, or of less stringency, for example, a
temperature of 37.degree. C. in the presence of a 2.times.SSC
buffer, respectively, require a globally less significant
complementarity for the hybridization between the two
sequences.
[0129] The stringent hybridization conditions described above for a
polynucleotide with a size of approximately 350 bases will be
adapted by a person skilled in the art for oligonucleotides of
greater or smaller size, according to the teachings of Sambrook et
al., 1989.
[0130] Among the isolated and/or purified nucleotide sequences
according to the invention, are those that can be used as a primer
or probe in methods allowing the homologous sequences according to
the invention to be obtained, these methods, such as the polymerase
chain reaction (PCR), nucleic acid cloning, and sequencing, being
well known to a person skilled in the art.
[0131] Among the isolated and/or purified nucleotide sequences
according to the invention, those are again preferred that can be
used as a primer or probe in methods allowing the presence of SEQ
ID NOS:2, 19, 36, 53, 70, 87, 104, 121, 138, 155, 172, 189, 206,
223, 240, 257, 274, 291, 308, 325, 342, 359, 376, 393, 410, 427,
444, 461, 478, 495, 512, 529, 546, 563, 580, 597, 614, 631, 648,
665, 682, 699, 716, 733, 750, 767, 784, 801, 818, 835, 852, 869,
886, 903, 920, 937, 954, 971, 988, 1005, 1022, 1039, 1056, 1073,
1090, 1107, 1124, 1141, 1158, 1175, 1192, 1209, 1226, 1243, 1260,
1277, 1294, 1311, 1328, 1345, 1362, 1379, 1396, 1413, 1430, 1447,
1464, 1481, 1498, 1515 1532, 1549, and 1566, one of their
fragments, or one of their variants such as defined below to be
diagnosed.
[0132] The nucleotide sequence fragments according to the invention
can be obtained, for example, by specific amplification, such as
PCR, or after digestion with appropriate restriction enzymes of
nucleotide sequences according to the invention, these methods in
particular being described in the work of Sambrook et al., 1989.
Such representative fragments can likewise be obtained by chemical
synthesis according to methods well known to persons of ordinary
skill in the art.
[0133] Modified nucleotide sequence will be understood as meaning
any nucleotide sequence obtained by mutagenesis according to
techniques well known to a person skilled in the art, and
containing modifications with respect to the normal sequences
according to the invention, for example, mutations in the
regulatory and/or promoter sequences of polypeptide expression,
especially leading to a modification of the rate of expression of
the polypeptide or to a modulation of the replicative cycle.
[0134] Modified nucleotide sequence will likewise be understood as
meaning any nucleotide sequence coding for a modified polypeptide,
such as defined below.
[0135] The present invention relates to nucleotide sequence
comprising isolated and/or purified nucleotide sequences of
Alicyclobacillus acidocaldarius, characterized in that they are
selected from the sequences of SEQ ID NOS:2, 19, 36, 53, 70, 87,
104, 121, 138, 155, 172, 189, 206, 223, 240, 257, 274, 291, 308,
325, 342, 359, 376, 393, 410, 427, 444, 461, 478, 495, 512, 529,
546, 563, 580, 597, 614, 631, 648, 665, 682, 699, 716, 733, 750,
767, 784, 801, 818, 835, 852, 869, 886, 903, 920, 937, 954, 971,
988, 1005, 1022, 1039, 1056, 1073, 1090, 1107, 1124, 1141, 1158,
1175, 1192, 1209, 1226, 1243, 1260, 1277, 1294, 1311, 1328, 1345,
1362, 1379, 1396, 1413, 1430, 1447, 1464, 1481, 1498, 1515, 1532,
1549, and 1566 or one of their fragments.
[0136] Embodiments of the invention likewise relate to isolated
and/or purified nucleotide sequences characterized in that they
comprise a nucleotide sequence selected from: a) at least one of a
nucleotide sequence of SEQ ID NOS:2, 19, 36, 53, 70, 87, 104, 121,
138, 155, 172, 189, 206, 223, 240, 257, 274, 291, 308, 325, 342,
359, 376, 393, 410, 427, 444, 461, 478, 495, 512, 529, 546, 563,
580, 597, 614, 631, 648, 665, 682, 699, 716, 733, 750, 767, 784,
801, 818, 835, 852, 869, 886, 903, 920, 937, 954, 971, 988, 1005,
1022, 1039, 1056, 1073, 1090, 1107, 1124, 1141, 1158, 1175, 1192,
1209, 1226, 1243, 1260, 1277, 1294, 1311, 1328, 1345, 1362, 1379,
1396, 1413, 1430, 1447, 1464, 1481, 1498, 1515, 1532, 1549, and
1566 or one of their fragments or one of their fragments; b) a
nucleotide sequence of a specific fragment of a sequence such as
defined in a); c) a homologous nucleotide sequence having at least
80% identity with a sequence such as defined in a) or b); d) a
complementary nucleotide sequence or sequence of RNA corresponding
to a sequence such as defined in a), b) or c); and e) a nucleotide
sequence modified by a sequence such as defined in a), b), c) or
d).
[0137] Among the isolated and/or purified nucleotide sequences
according to the invention are the nucleotide sequences of SEQ ID
NOS:13-17, 30-34, 47-51, 64-68, 81-85, 98-102, 115-119, 132-136,
149-153, 166-170, 183-187, 200-204, 217-221, 234-238, 251-255,
268-272, 285-289, 302-306, 319-323, 336-340, 353-357, 370-374,
387-391, 404-408, 421-425, 438-442, 455-459, 472-476, 489-493,
506-510, 523-527, 540-544, 557-561, 574-578, 591-595, 608-612,
625-629, 642-646, 659-663, 676-680, 693-697, 710-714, 727-731,
744-748, 761-765, 778-782, 795-799, 812-816, 829-833, 846-850,
863-867, 880-884, 897-901, 914-918, 931-935, 948-952, 965-969,
982-986, 999-1003, 1016-1020, 1033-1037, 1050-1054, 1067-1071,
1084-1088, 1101-1105, 1118-1122, 1135-1139, 1152-1156, 1169-1173,
1186-1190, 1203-1207, 1220-1224, 1237-1241, 1254-1258, 1271-1275,
1288-1292, 1305-1309, 1322-1326, 1339-1343, 1356-1360, 1373-1377,
1390-1394, 1407-1411, 1424-1428, 1441-1445, 1458-1462, 1475-1479,
1492-1496, 1509-1513, 1526-1530, 1543-1547, 1560-1564, and
1577-1581, or fragments thereof and any isolated and/or purified
nucleotide sequences, which have a homology of at least 80%, 81%,
82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%,
95%, 96%, 97%, 98%, 99%, 99.5%, 99.6%, or 99.7% identity with the
at least one of the sequences of SEQ ID NOS:2, 19, 36, 53, 70, 87,
104, 121, 138, 155, 172, 189, 206, 223, 240, 257, 274, 291, 308,
325, 342, 359, 376, 393, 410, 427, 444, 461, 478, 495, 512, 529,
546, 563, 580, 597, 614, 631, 648, 665, 682, 699, 716, 733, 750,
767, 784, 801, 818, 835, 852, 869, 886, 903, 920, 937, 954, 971,
988, 1005, 1022, 1039, 1056, 1073, 1090, 1107, 1124, 1141, 1158,
1175, 1192, 1209, 1226, 1243, 1260, 1277, 1294, 1311, 1328, 1345,
1362, 1379, 1396, 1413, 1430, 1447, 1464, 1481, 1498, 1515, 1532,
1549, and 1566 or fragments thereof. Such homologous sequences can
comprise, for example, the sequences corresponding to the genomic
sequences of Alicyclobacillus acidocaldarius. In the same manner,
these specific homologous sequences can correspond to variations
linked to mutations within strains of Alicyclobacillus
acidocaldarius and especially correspond to truncations,
substitutions, deletions and/or additions of at least one
nucleotide. As will be apparent to one of ordinary skill in the
art, such homologues are easily created and identified using
conventional techniques and publicly available computer programs
such as BLAST. Accordingly, each homologue referenced above should
be considered as set forth herein and fully described.
[0138] Embodiments of the invention comprise the isolated and/or
purified polypeptides coded for by a nucleotide sequence according
to the invention, or fragments thereof, whose sequence is
represented by a fragment. Amino acid sequences corresponding to
the isolated and/or purified polypeptides that can be coded for
according to one of the three possible reading frames of at least
one of the sequences of SEQ ID NOS:2, 19, 36, 53, 70, 87, 104, 121,
138, 155, 172, 189, 206, 223, 240, 257, 274, 291, 308, 325, 342,
359, 376, 393, 410, 427, 444, 461, 478, 495, 512, 529, 546, 563,
580, 597, 614, 631, 648, 665, 682, 699, 716, 733, 750, 767, 784,
801, 818, 835, 852, 869, 886, 903, 920, 937, 954, 971, 988, 1005,
1022, 1039, 1056, 1073, 1090, 1107, 1124, 1141, 1158, 1175, 1192,
1209, 1226, 1243, 1260, 1277, 1294, 1311, 1328, 1345, 1362, 1379,
1396, 1413, 1430, 1447, 1464, 1481, 1498, 1515, 1532, 1549, and
1566.
[0139] Embodiments of the invention likewise relate to the isolated
and/or purified polypeptides, characterized in that they comprise a
polypeptide selected from at least one of the amino acid sequences
of SEQ ID NOS:1, 18, 35, 52, 69, 86, 103, 120, 137, 154, 171, 188,
205, 222, 239, 256, 273, 290, 307, 324, 341, 358, 375, 392, 409,
426, 443, 460, 477, 494, 511, 528, 545, 562, 579, 596, 613, 630,
647, 664, 681, 698, 715, 732, 749, 766, 783, 800, 817, 834, 851,
868, 885, 902, 819, 936, 953, 970, 987, 1004, 1021, 1038, 1055,
1072, 1089, 1106, 1123, 1140, 1157, 1174, 1191, 1208, 1225, 1242,
1259, 1276, 1293, 1310, 1327, 1344, 1361, 1378, 1395, 1412, 1429,
1446, 1463, 1480, 1497, 1514, 1531, 1548, and 1565 or one of their
fragments.
[0140] Among the isolated and/or purified polypeptides, according
to embodiments of the invention, are the isolated and/or purified
polypeptides of amino acid sequence SEQ ID NOS:8-12, 25-29, 42-46,
59-63, 76-80, 93-97, 110-114, 127-131, 144-148, 161-165, 178-182,
195-199, 212-216, 229-233, 246-250, 263-267, 280-284, 297-301,
314-318, 331-335, 348-352, 365-369, 382-386, 399-403, 416-420,
433-437, 450-454, 467-471, 484-488, 501-505, 518-522, 535-539,
552-556, 569-573, 586-590, 603-607, 620-624, 637-641, 654-658,
671-675, 688-692, 705-709, 722-726, 739-743, 756-760, 773-777,
790-794, 807-811, 824-828, 841-845, 858-862, 875-879, 892-896,
909-913, 926-930, 943-947, 960-964, 977-981, 994-998, 1011-1015,
1028-1032, 1045-1049, 1062-1066, 1079-1083, 1096-1100, 1113-1117,
1130-1134, 1147-1151, 1164-1168, 1181-1185, 1198-1202, 1215-1219,
1232-1236, 1249-1253, 1266-1270, 1283-1287, 1300-1304, 1317-1321,
1334-1338, 1351-1355, 1368-1372, 1385-1389, 1402-1406, 1419-1423,
1436-1440, 1453-1457, 1470-1474, 1487-1491, 1504-1508, 1521-1525,
1538-1542, 1555-1559, and 1572-1576, or fragments thereof or any
other isolated and/or purified polypeptides that have a homology of
at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%,
91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.6%, or 99.7%
identity with at least one of the sequences of SEQ ID NOS:1, 18,
35, 52, 69, 86, 103, 120, 137, 154, 171, 188, 205, 222, 239, 256,
273, 290, 307, 324, 341, 358, 375, 392, 409, 426, 443, 460, 477,
494, 511, 528, 545, 562, 579, 596, 613, 630, 647, 664, 681, 698,
715, 732, 749, 766, 783, 800, 817, 834, 851, 868, 885, 902, 819,
936, 953, 970, 987, 1004, 1021, 1038, 1055, 1072, 1089, 1106, 1123,
1140, 1157, 1174, 1191, 1208, 1225, 1242, 1259, 1276, 1293, 1310,
1327, 1344, 1361, 1378, 1395, 1412, 1429, 1446, 1463, 1480, 1497,
1514, 1531, 1548, and 1565 or fragments thereof. As will be
apparent to one of ordinary skill in the art, such homologues are
easily created and identified using conventional techniques and
publicly available computer programs such as BLAST. Accordingly,
each homologue referenced above should be considered as set forth
herein and fully described.
[0141] Embodiments of the invention also relate to the
polypeptides, characterized in that they comprise a polypeptide
selected from: a) a specific fragment of at least 5 amino acids of
a polypeptide of an amino acid sequence according to the invention;
b) a polypeptide homologous to a polypeptide such as defined in a);
c) a specific biologically active fragment of a polypeptide such as
defined in a) or b); and d) a polypeptide modified by a polypeptide
such as defined in a), b) or c).
[0142] In the present description, the terms polypeptide, peptide
and protein are interchangeable.
[0143] In embodiments of the invention, the isolated and/or
purified polypeptides according to the invention may be
glycosylated, pegylated, and/or otherwise post-translationally
modified. In further embodiments, glycosylation, pegylation, and/or
other post-translational modifications may occur in vivo or in
vitro and/or may be performed using chemical techniques. In
additional embodiments, any glycosylation, pegylation and/or other
post-translational modifications may be N-linked or O-linked.
[0144] In embodiments of the invention any one of the isolated
and/or purified polypeptides according to the invention may be
enzymatically or functionally active at temperatures at or above
about 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90,
and/or 95 degrees Celsius and/or may be enzymatically or
functionally active at a pH at, below, and/or above 8, 7, 6, 5, 4,
3, 2, 1, and/or 0. In further embodiments of the invention,
glycosylation, pegylation, and/or other post-translational
modification may be required for the isolated and/or purified
polypeptides according to the invention to be enzymatically or
functionally active at a pH at or below 8, 7, 6, 5, 4, 3, 2, 1,
and/or 0 or at temperatures at or above about 25, 30, 35, 40, 45,
50, 55, 60, 65, 70, 75, 80, 85, 90, and/or 95 degrees Celsius.
[0145] Aspects of the invention relate to polypeptides that are
isolated or obtained by purification from natural sources, or else
obtained by genetic recombination, or alternatively by chemical
synthesis and that they may thus contain unnatural amino acids, as
will be described below.
[0146] A "polypeptide fragment" according to the embodiments of the
invention is understood as designating a polypeptide containing at
least 5 consecutive amino acids, preferably 10 consecutive amino
acids or 15 consecutive amino acids.
[0147] In the present invention, a specific polypeptide fragment is
understood as designating the consecutive polypeptide fragment
coded for by a specific fragment nucleotide sequence according to
the invention.
[0148] "Homologous polypeptide" will be understood as designating
the polypeptides having, with respect to the natural polypeptide,
certain modifications such as, in particular, a deletion, addition,
or substitution of at least one amino acid, a truncation, a
prolongation, a chimeric fusion, and/or a mutation. Among the
homologous polypeptides, those are preferred whose amino acid
sequence has at least 80% or 90%, homology with the sequences of
amino acids of polypeptides according to the invention.
[0149] "Specific homologous polypeptide" will be understood as
designating the homologous polypeptides such as defined above and
having a specific fragment of polypeptide according to the
invention.
[0150] In the case of a substitution, one or more consecutive or
nonconsecutive amino acids are replaced by "equivalent" amino
acids. The expression "equivalent" amino acid is directed here at
designating any amino acid capable of being substituted by one of
the amino acids of the base structure without, however, essentially
modifying the biological activities of the corresponding peptides
and such that they will be defined by the following. As will be
apparent to one of ordinary skill in the art, such substitutions
are easily created and identified using standard molecular biology
techniques and publicly available computer programs such as BLAST.
Accordingly, each substitution referenced above should be
considered as set forth herein and fully described. Examples of
such substitutions in the amino acid sequences of SEQ ID NOS:1, 18,
35, 52, 69, 86, 103, 120, 137, 154, 171, 188, 205, 222, 239, 256,
273, 290, 307, 324, 341, 358, 375, 392, 409, 426, 443, 460, 477,
494, 511, 528, 545, 562, 579, 596, 613, 630, 647, 664, 681, 698,
715, 732, 749, 766, 783, 800, 817, 834, 851, 868, 885, 902, 819,
936, 953, 970, 987, 1004, 1021, 1038, 1055, 1072, 1089, 1106, 1123,
1140, 1157, 1174, 1191, 1208, 1225, 1242, 1259, 1276, 1293, 1310,
1327, 1344, 1361, 1378, 1395, 1412, 1429, 1446, 1463, 1480, 1497,
1514, 1531, 1548, and 1565 may include those isolated and/or
purified polypeptides of amino acid sequence SEQ ID NOS:8-12,
25-29, 42-46, 59-63, 76-80, 93-97, 110-114, 127-131, 144-148,
161-165, 178-182, 195-199, 212-216, 229-233, 246-250, 263-267,
280-284, 297-301, 314-318, 331-335, 348-352, 365-369, 382-386,
399-403, 416-420, 433-437, 450-454, 467-471, 484-488, 501-505,
518-522, 535-539, 552-556, 569-573, 586-590, 603-607, 620-624,
637-641, 654-658, 671-675, 688-692, 705-709, 722-726, 739-743,
756-760, 773-777, 790-794, 807-811, 824-828, 841-845, 858-862,
875-879, 892-896, 909-913, 926-930, 943-947, 960-964, 977-981,
994-998, 1011-1015, 1028-1032, 1045-1049, 1062-1066, 1079-1083,
1096-1100, 1113-1117, 1130-1134, 1147-1151, 1164-1168, 1181-1185,
1198-1202, 1215-1219, 1232-1236, 1249-1253, 1266-1270, 1283-1287,
1300-1304, 1317-1321, 1334-1338, 1351-1355, 1368-1372, 1385-1389,
1402-1406, 1419-1423, 1436-1440, 1453-1457, 1470-1474, 1487-1491,
1504-1508, 1521-1525, 1538-1542, 1555-1559, and 1572-1576. These
equivalent amino acids may be determined either by depending on
their structural homology with the amino acids that they
substitute, or on results of comparative tests of biological
activity between the different polypeptides, which are capable of
being carried out.
[0151] By way of non-limiting example, the possibilities of
substitutions capable of being carried out without resulting in an
extensive modification of the biological activity of the
corresponding modified polypeptides will be mentioned, the
replacement, for example, of leucine by valine or isoleucine, of
aspartic acid by glutamic acid, of glutamine by asparagine, of
arginine by lysine, etc., the reverse substitutions naturally being
envisageable under the same conditions.
[0152] In a further embodiment, substitutions are limited to
substitutions in amino acids not conserved among other proteins
that have similar identified enzymatic activity. For example, one
of ordinary skill in the art may align proteins of the same
function in similar organisms and determine which amino acids are
generally conserved among proteins of that function. One example of
a program that may be used to generate such alignments is available
at the web site charite.de/bioinf/strap/ in conjunction with the
databases provided by the NCBI. Examples of such polypeptides may
include, but are not limited to, those found in amino acid sequence
SEQ ID NOS:8-12, 25-29, 42-46, 59-63, 76-80, 93-97, 110-114,
127-131, 144-148, 161-165, 178-182, 195-199, 212-216, 229-233,
246-250, 263-267, 280-284, 297-301, 314-318, 331-335, 348-352,
365-369, 382-386, 399-403, 416-420, 433-437, 450-454, 467-471,
484-488, 501-505, 518-522, 535-539, 552-556, 569-573, 586-590,
603-607, 620-624, 637-641, 654-658, 671-675, 688-692, 705-709,
722-726, 739-743, 756-760, 773-777, 790-794, 807-811, 824-828,
841-845, 858-862, 875-879, 892-896, 909-913, 926-930, 943-947,
960-964, 977-981, 994-998, 1011-1015, 1028-1032, 1045-1049,
1062-1066, 1079-1083, 1096-1100, 1113-1117, 1130-1134, 1147-1151,
1164-1168, 1181-1185, 1198-1202, 1215-1219, 1232-1236, 1249-1253,
1266-1270, 1283-1287, 1300-1304, 1317-1321, 1334-1338, 1351-1355,
1368-1372, 1385-1389, 1402-1406, 1419-1423, 1436-1440, 1453-1457,
1470-1474, 1487-1491, 1504-1508, 1521-1525, 1538-1542, 1555-1559,
and 1572-1576.
[0153] Thus, according to one embodiment of the invention,
substitutions or mutations may be made at positions that are
generally conserved among proteins of that function. In a further
embodiment, nucleic acid sequences may be mutated or substituted
such that the amino acid they code for is unchanged (degenerate
substitutions and/or mutations) and/or mutated or substituted such
that any resulting amino acid substitutions or mutations are made
at positions that are generally conserved among proteins of that
function. Examples of such nucleic acid sequences may include, but
are not limited to, those found in are the nucleotide sequences of
SEQ ID NOS:13-17, 30-34, 47-51, 64-68, 81-85, 98-102, 115-119,
132-136, 149-153, 166-170, 183-187, 200-204, 217-221, 234-238,
251-255, 268-272, 285-289, 302-306, 319-323, 336-340, 353-357,
370-374, 387-391, 404-408, 421-425, 438-442, 455-459, 472-476,
489-493, 506-510, 523-527, 540-544, 557-561, 574-578, 591-595,
608-612, 625-629, 642-646, 659-663, 676-680, 693-697, 710-714,
727-731, 744-748, 761-765, 778-782, 795-799, 812-816, 829-833,
846-850, 863-867, 880-884, 897-901, 914-918, 931-935, 948-952,
965-969, 982-986, 999-1003, 1016-1020, 1033-1037, 1050-1054,
1067-1071, 1084-1088, 1101-1105, 1118-1122, 1135-1139, 1152-1156,
1169-1173, 1186-1190, 1203-1207, 1220-1224, 1237-1241, 1254-1258,
1271-1275, 1288-1292, 1305-1309, 1322-1326, 1339-1343, 1356-1360,
1373-1377, 1390-1394, 1407-1411, 1424-1428, 1441-1445, 1458-1462,
1475-1479, 1492-1496, 1509-1513, 1526-1530, 1543-1547, 1560-1564,
1577-1581 or fragments thereof.
[0154] The specific homologous polypeptides likewise correspond to
polypeptides coded for by the specific homologous nucleotide
sequences such as defined above and thus comprise in the present
definition the polypeptides, which are mutated or correspond to
variants that can exist in Alicyclobacillus acidocaldarius, and
that especially correspond to truncations, substitutions,
deletions, and/or additions of at least one amino acid residue.
[0155] "Specific biologically active fragment of a polypeptide"
according to an embodiment of the invention will be understood in
particular as designating a specific polypeptide fragment, such as
defined above, having at least one of the characteristics of
polypeptides according to the invention. In certain embodiments the
peptide is capable of behaving as at least one of the types of
proteins outlined in Table 1.
[0156] The polypeptide fragments according to embodiments of the
invention can correspond to isolated or purified fragments
naturally present in Alicyclobacillus acidocaldarius or correspond
to fragments that can be obtained by cleavage of the polypeptide by
a proteolytic enzyme, such as trypsin or chymotrypsin or
collagenase, or by a chemical reagent, such as cyanogen bromide
(CNBr). Such polypeptide fragments can likewise just as easily be
prepared by chemical synthesis, from hosts transformed by an
expression vector according to the invention containing a nucleic
acid allowing the expression of the fragments, placed under the
control of appropriate regulation and/or expression elements.
[0157] "Modified polypeptide" of a polypeptide according to an
embodiment of the invention is understood as designating a
polypeptide obtained by genetic recombination or by chemical
synthesis as will be described below, having at least one
modification with respect to the normal sequence. These
modifications may or may not be able to bear on amino acids at the
origin of specificity, and/or of activity, or at the origin of the
structural conformation, localization, and of the capacity of
membrane insertion of the polypeptide according to the invention.
It will thus be possible to create polypeptides of equivalent,
increased, or decreased activity, and of equivalent, narrower, or
wider specificity. Among the modified polypeptides, it is necessary
to mention the polypeptides in which up to 5 or more amino acids
can be modified, truncated at the N- or C-terminal end, or even
deleted or added.
[0158] The methods allowing the modulations on eukaryotic or
prokaryotic cells to be demonstrated are well known to a person of
ordinary skill in the art. It is likewise well understood that it
will be possible to use the nucleotide sequences coding for the
modified polypeptides for the modulations, for example, through
vectors according to the invention and described below.
[0159] The preceding modified polypeptides can be obtained by using
combinatorial chemistry, in which it is possible to systematically
vary parts of the polypeptide before testing them on models, cell
cultures or microorganisms, for example, to select the compounds
that are most active or have the properties sought.
[0160] Chemical synthesis likewise has the advantage of being able
to use nonnatural amino acids, or nonpeptide bonds.
[0161] Thus, in order to improve the duration of life of the
polypeptides according to the invention, it may be of interest to
use nonnatural amino acids, for example, in D form, or else amino
acid analogs, especially sulfur-containing forms, for example.
[0162] Finally, it will be possible to integrate the structure of
the polypeptides according to the invention, its specific or
modified homologous forms, into chemical structures of polypeptide
type or others. Thus, it may be of interest to provide at the N-
and C-terminal ends molecules not recognized by proteases.
[0163] The nucleotide sequences coding for a polypeptide according
to the invention are likewise part of the invention.
[0164] The invention likewise relates to nucleotide sequences
utilizable as a primer or probe, characterized in that the
sequences are selected from the nucleotide sequences according to
the invention.
[0165] It is well understood that the present invention, in various
embodiments, likewise relates to specific polypeptides of
Alicyclobacillus acidocaldarius, coded for by nucleotide sequences,
capable of being obtained by purification from natural
polypeptides, by genetic recombination or by chemical synthesis by
procedures well known to a person skilled in the art and such as
described in particular below. In the same manner, the labeled or
unlabeled mono- or polyclonal antibodies directed against the
specific polypeptides coded for by the nucleotide sequences are
also encompassed by the invention.
[0166] Embodiments of the invention additionally relate to the use
of a nucleotide sequence according to the invention as a primer or
probe for the detection and/or the amplification of nucleic acid
sequences.
[0167] The nucleotide sequences according to embodiments of the
invention can thus be used to amplify nucleotide sequences,
especially by the PCR technique (polymerase chain reaction)
(Erlich. 1989; Innis et al., 1990; Rolfs et al., 1991; and White et
al., 1997).
[0168] These oligodeoxyribonucleotide or oligoribonucleotide
primers advantageously have a length of at least 8 nucleotides,
preferably of at least 12 nucleotides, and even more preferentially
of at least 20 nucleotides.
[0169] Other amplification techniques of the target nucleic acid
can be advantageously employed as alternatives to PCR.
[0170] The nucleotide sequences of the invention, in particular the
primers according to the invention, can likewise be employed in
other procedures of amplification of a target nucleic acid, such
as: the TAS technique (Transcription-based Amplification System),
described by Kwoh et al. in 1989; the 3SR technique (Self-Sustained
Sequence Replication), described by Guatelli et al. in 1990; the
NASBA technique (Nucleic Acid Sequence Based Amplification),
described by Kievitis et al. in 1991; the SDA technique (Strand
Displacement Amplification) (Walker et al., 1992); and the TMA
technique (Transcription Mediated Amplification).
[0171] The polynucleotides of the invention can also be employed in
techniques of amplification or of modification of the nucleic acid
serving as a probe, such as: the LCR technique (Ligase Chain
Reaction), described by Landegren et al. in 1988 and improved by
Barany et al. in 1991, which employs a thermostable ligase; the RCR
technique (Repair Chain Reaction), described by Segev in 1992; the
CPR technique (Cycling Probe Reaction), described by Duck et al. in
1990; the amplification technique with Q-beta replicase, described
by Miele et al. in 1983 and especially improved by Chu et al. in
1986, Lizardi et al. in 1988, then by Burg et al., as well as by
Stone et al. in 1996.
[0172] In the case where the target polynucleotide to be detected
is possibly an RNA, for example, an mRNA, it will be possible to
use, prior to the employment of an amplification reaction with the
aid of at least one primer according to the invention or to the
employment of a detection procedure with the aid of at least one
probe of the invention, an enzyme of reverse transcriptase type in
order to obtain a cDNA from the RNA contained in the biological
sample. The cDNA obtained will thus serve as a target for the
primer(s) or the probe(s) employed in the amplification or
detection procedure according to the invention.
[0173] The detection probe will be chosen in such a manner that it
hybridizes with the target sequence or the amplicon generated from
the target sequence. By way of sequence, such a probe will
advantageously have a sequence of at least 12 nucleotides, in
particular of at least 20 nucleotides, and preferably of at least
100 nucleotides.
[0174] Embodiments of the invention also comprise the nucleotide
sequences utilizable as a probe or primer according to the
invention, characterized in that they are labeled with a
radioactive compound or with a nonradioactive compound.
[0175] The unlabeled nucleotide sequences can be used directly as
probes or primers, although the sequences are generally labeled
with a radioactive isotope (.sup.32P, .sup.35S, .sup.3H, .sup.125I)
or with a nonradioactive molecule (biotin, acetylaminofluorene,
digoxigenin, 5-bromodeoxyuridine, fluorescein) to obtain probes
that are utilizable for numerous applications.
[0176] Examples of nonradioactive labeling of nucleotide sequences
are described, for example, in French Patent No. 7810975 or by
Urdea et al. or by Sanchez-Pescador et al. in 1988.
[0177] In the latter case, it will also be possible to use one of
the labeling methods described in patents FR-2 422 956 and FR-2 518
755.
[0178] The hybridization technique can be carried out in various
manners (Matthews et al., 1988). The most general method consists
in immobilizing the nucleic acid extract of cells on a support
(such as nitrocellulose, nylon, polystyrene) and in incubating,
under well-defined conditions, the immobilized target nucleic acid
with the probe. After hybridization, the excess of probe is
eliminated and the hybrid molecules formed are detected by the
appropriate method (measurement of the radioactivity, of the
fluorescence or of the enzymatic activity linked to the probe).
[0179] The invention, in various embodiments, likewise comprises
the nucleotide sequences according to the invention, characterized
in that they are immobilized on a support, covalently or
noncovalently.
[0180] According to another advantageous mode of employing
nucleotide sequences according to the invention, the latter can be
used immobilized on a support and can thus serve to capture, by
specific hybridization, the target nucleic acid obtained from the
biological sample to be tested. If necessary, the solid support is
separated from the sample and the hybridization complex formed
between the capture probe and the target nucleic acid is then
detected with the aid of a second probe, a so-called detection
probe, labeled with an easily detectable element.
[0181] Another aspect of the present invention is a vector for the
cloning and/or expression of a sequence, characterized in that it
contains a nucleotide sequence according to the invention.
[0182] The vectors, according to the invention, characterized in
that they contain the elements allowing the integration, expression
and/or the secretion of the nucleotide sequences in a determined
host cell, are likewise part of the invention.
[0183] The vector may then contain a promoter, signals of
initiation and termination of translation, as well as appropriate
regions of regulation of transcription. It may be able to be
maintained stably in the host cell and can optionally have
particular signals specifying the secretion of the translated
protein. These different elements may be chosen as a function of
the host cell used. To this end, the nucleotide sequences according
to the invention may be inserted into autonomous replication
vectors within the chosen host, or integrated vectors of the chosen
host.
[0184] Such vectors will be prepared according to the methods
currently used by a person skilled in the art, and it will be
possible to introduce the clones resulting therefrom into an
appropriate host by standard methods, such as, for example,
lipofection, electroporation, and thermal shock.
[0185] The vectors according to the invention are, for example,
vectors of plasmid or viral origin. One example of a vector for the
expression of polypeptides of the invention is Baculovirus.
[0186] These vectors are useful for transforming host cells in
order to clone or to express the nucleotide sequences of the
invention.
[0187] The invention likewise comprises the host cells transformed
by a vector according to the invention.
[0188] These cells can be obtained by the introduction into host
cells of a nucleotide sequence inserted into a vector such as
defined above, then the culturing of the cells under conditions
allowing the replication and/or expression of the transfected
nucleotide sequence.
[0189] The host cell can be selected from prokaryotic or eukaryotic
systems, such as, for example, bacterial cells (Olins and Lee,
1993), but likewise yeast cells (Buckholz, 1993), as well as plants
cells, such as Arabidopsis sp., and animal cells, in particular the
cultures of mammalian cells (Edwards and Aruffo, 1993), for
example, Chinese hamster ovary (CHO) cells, but likewise the cells
of insects in which it is possible to use procedures employing
baculoviruses, for example. Sf9 insect cells (Luckow, 1993).
[0190] Embodiments of the invention likewise relate to organisms
comprising one of the transformed cells according to the
invention.
[0191] The obtainment of transgenic organisms, according to the
invention, of expressing one or more of the genes of
Alicyclobacillus acidocaldarius or part of the genes may be carried
out in, for example, rats, mice, or rabbits according to methods
well known to a person skilled in the art, such as by viral or
nonviral transfections. It will be possible to obtain the
transgenic organisms expressing one or more of the genes by
transfection of multiple copies of the genes under the control of a
strong promoter of ubiquitous nature, or selective for one type of
tissue. It will likewise be possible to obtain the transgenic
organisms by homologous recombination in embryonic cell strains,
transfer of these cell strains to embryos, selection of the
affected chimeras at the level of the reproductive lines, and
growth of the chimeras.
[0192] The transformed cells, as well as the transgenic organisms
according to the invention, are utilizable in procedures for
preparation of recombinant polypeptides.
[0193] It is today possible to produce recombinant polypeptides in
relatively large quantity by genetic engineering using the cells
transformed by expression vectors according to the invention or
using transgenic organisms according to the invention.
[0194] The procedures for preparation of a polypeptide of the
invention in recombinant form, characterized in that they employ a
vector and/or a cell transformed by a vector according to the
invention and/or a transgenic organism comprising one of the
transformed cells according to the invention are themselves
comprised in the present invention.
[0195] As used herein, "transformation" and "transformed" relate to
the introduction of nucleic acids into a cell, whether prokaryotic
or eukaryotic. Further, "transformation" and "transformed," as used
herein, need not relate to growth control or growth
deregulation.
[0196] Among the procedures for preparation of a polypeptide of the
invention in recombinant form, the preparation procedures employing
a vector, and/or a cell transformed by the vector and/or a
transgenic organism comprising one of the transformed cells,
containing a nucleotide sequence according to the invention coding
for a polypeptide of Alicyclobacillus acidocaldarius.
[0197] A variant according to the invention may consist of
producing a recombinant polypeptide fused to a "carrier" protein
(chimeric protein). The advantage of this system is that it may
allow stabilization of and/or a decrease in the proteolysis of the
recombinant product, an increase in the solubility in the course of
renaturation in vitro and/or a simplification of the purification
when the fusion partner has an affinity for a specific ligand.
[0198] More particularly, the invention relates to a procedure for
preparation of a polypeptide of the invention comprising the
following steps: a) culture of transformed cells under conditions
allowing the expression of a recombinant polypeptide of a
nucleotide sequence according to the invention; b) if need be,
recovery of the recombinant polypeptide.
[0199] When the procedure for preparation of a polypeptide of the
invention employs a transgenic organism according to the invention,
the recombinant polypeptide is then extracted from the
organism.
[0200] The invention also relates to a polypeptide that is capable
of being obtained by a procedure of the invention such as described
previously.
[0201] The invention also comprises a procedure for preparation of
a synthetic polypeptide, characterized in that it uses a sequence
of amino acids of polypeptides according to the invention.
[0202] The invention likewise relates to a synthetic polypeptide
obtained by a procedure according to the invention.
[0203] The polypeptides according to the invention can likewise be
prepared by techniques that are conventional in the field of the
synthesis of peptides. This synthesis can be carried out in
homogeneous solution or in solid phase.
[0204] For example, recourse can be made to the technique of
synthesis in an homogeneous solution described by Houben-Weyl in
1974.
[0205] This method of synthesis consists in successively
condensing, two by two, the successive amino acids in the order
required, or in condensing amino acids and fragments formed
previously and already containing several amino acids in the
appropriate order, or alternatively several fragments previously
prepared in this way, it being understood that it will be necessary
to protect beforehand all the reactive functions carried by these
amino acids or fragments, with the exception of amine functions of
one and carboxyls of the other or vice-versa, which must normally
be involved in the formation of peptide bonds, especially after
activation of the carboxyl function, according to the methods well
known in the synthesis of peptides.
[0206] Recourse may also be made to the technique described by
Merrifield.
[0207] To make a peptide chain according to the Merrifield
procedure, recourse is made to a very porous polymeric resin, on
which is immobilized the first C-terminal amino acid of the chain.
This amino acid is immobilized on a resin through its carboxyl
group and its amine function is protected. The amino acids that are
going to form the peptide chain are thus immobilized, one after the
other, on the amino group, which is deprotected beforehand each
time, of the portion of the peptide chain already formed, and which
is attached to the resin. When the whole of the desired peptide
chain has been formed, the protective groups of the different amino
acids forming the peptide chain are eliminated and the peptide is
detached from the resin with the aid of an acid.
[0208] The invention additionally relates to hybrid polypeptides
having at least one polypeptide according to the invention, and a
sequence of a polypeptide capable of inducing an immune response in
man or animals.
[0209] Advantageously, the antigenic determinant is such that it is
capable of inducing a humoral and/or cellular response.
[0210] It will be possible for such a determinant to comprise a
polypeptide according to the invention in glycosylated, pegylated,
and/or otherwise post-translationally modified form used with a
view to obtaining immunogenic compositions capable of inducing the
synthesis of antibodies directed against multiple epitopes.
[0211] These hybrid molecules can be formed, in part, of a
polypeptide carrier molecule or of fragments thereof according to
the invention, associated with a possibly immunogenic part, in
particular, an epitope of the diphtheria toxin, the tetanus toxin,
a surface antigen of the hepatitis B virus (Patent FR 79 21811),
the VP1 antigen of the poliomyelitis virus or any other viral or
bacterial toxin or antigen.
[0212] The procedures for synthesis of hybrid molecules encompass
the methods used in genetic engineering for constructing hybrid
nucleotide sequences coding for the polypeptide sequences sought.
It will be possible, for example, to refer advantageously to the
technique for obtainment of genes coding for fusion proteins
described by Minton in 1984.
[0213] The hybrid nucleotide sequences coding for a hybrid
polypeptide as well as the hybrid polypeptides according to the
invention characterized in that they are recombinant polypeptides
obtained by the expression of the hybrid nucleotide sequences are
likewise part of the invention.
[0214] The invention likewise comprises the vectors characterized
in that they contain one of the hybrid nucleotide sequences. The
host cells transformed by the vectors, the transgenic organisms
comprising one of the transformed cells as well as the procedures
for preparation of recombinant polypeptides using the vectors, the
transformed cells and/or the transgenic organisms are, of course,
likewise part of the invention.
[0215] The polypeptides according to the invention, the antibodies
according to the invention described below and the nucleotide
sequences according to the invention can advantageously be employed
in procedures for the detection and/or identification of
Alicyclobacillus acidocaldarius, in a sample capable of containing
them. These procedures, according to the specificity of the
polypeptides, the antibodies and the nucleotide sequences according
to the invention that will be used, will in particular be able to
detect and/or to identify Alicyclobacillus acidocaldarius.
[0216] The polypeptides according to the invention can
advantageously be employed in a procedure for the detection and/or
the identification of Alicyclobacillus acidocaldarius in a sample
capable of containing them, characterized in that it comprises the
following steps: a) contacting of this sample with a polypeptide or
one of its fragments according to the invention (under conditions
allowing an immunological reaction between the polypeptide and the
antibodies possibly present in the biological sample); and b)
demonstration of the antigen-antibody complexes possibly
formed.
[0217] Any conventional procedure can be employed for carrying out
such a detection of the antigen-antibody complexes possibly
formed.
[0218] By way of non-limiting example, one method brings into play
immunoenzymatic processes according to the ELISA technique, by
immunofluorescence, or radioimmunological processes (RIA) or their
equivalent.
[0219] Thus, the invention likewise relates to the polypeptides
according to the invention, labeled with the aid of an adequate
label, such as, of the enzymatic, fluorescent or radioactive
type.
[0220] Such methods comprise, for example, the following acts:
deposition of determined quantities of a polypeptide composition
according to the invention in the wells of a microtiter plate,
introduction into the wells of increasing dilutions of serum, or of
a biological sample other than that defined previously, having to
be analyzed, incubation of the wells of the microtiter plate,
introduction into the wells of the microtiter plate of labeled
antibodies directed against pig immunoglobulins, the labeling of
these antibodies having been carried out with the aid of an enzyme
selected from those that are capable of hydrolyzing a substrate by
modifying the absorption of the radiation of the latter, at least
at a determined wavelength, for example at 550 nm, detection, by
comparison with a control test, of the quantity of hydrolyzed
substrate.
[0221] The polypeptides according to the invention allow monoclonal
or polyclonal antibodies to be prepared, which are characterized in
that they specifically recognize the polypeptides according to the
invention. It will advantageously be possible to prepare the
monoclonal antibodies from hybridomas according to the technique
described by Kohler and Milstein in 1975. It will be possible to
prepare the polyclonal antibodies, for example, by immunization of
an animal, in particular a mouse, with a polypeptide or a DNA,
according to the invention, associated with an adjuvant of the
immune response, and then purification of the specific antibodies
contained in the serum of the immunized animals on an affinity
column on which the polypeptide, which has served as an antigen,
has previously been immobilized. The polyclonal antibodies
according to the invention can also be prepared by purification, on
an affinity column on which a polypeptide according to the
invention has previously been immobilized, of the antibodies
contained in the serum of an animal immunologically challenged by
Alicyclobacillus acidocaldarius, or a polypeptide or fragment
according to the invention.
[0222] The invention likewise relates to mono- or polyclonal
antibodies or their fragments, or chimeric antibodies,
characterized in that they are capable of specifically recognizing
a polypeptide according to the invention.
[0223] It will likewise be possible for the antibodies of the
invention to be labeled in the same manner as described previously
for the nucleic probes of the invention, such as a labeling of
enzymatic, fluorescent or radioactive type.
[0224] The invention is additionally directed at a procedure for
the detection and/or identification of Alicyclobacillus
acidocaldarius in a sample, characterized in that it comprises the
following steps: a) contacting of the sample with a mono- or
polyclonal antibody according to the invention (under conditions
allowing an immunological reaction between the antibodies and the
polypeptides of Alicyclobacillus acidocaldarius possibly present in
the biological sample); and b) demonstration of the
antigen-antibody complex possibly formed.
[0225] The present invention likewise relates to a procedure for
the detection and/or the identification of Alicyclobacillus
acidocaldarius in a sample, characterized in that it employs a
nucleotide sequence according to the invention.
[0226] More particularly, the invention relates to a procedure for
the detection and/or the identification of Alicyclobacillus
acidocaldarius in a sample, characterized in that it contains the
following steps: a) if need be, isolation of the DNA from the
sample to be analyzed; b) specific amplification of the DNA of the
sample with the aid of at least one primer, or a pair of primers,
according to the invention; and c) demonstration of the
amplification products.
[0227] These can be detected, for example, by the technique of
molecular hybridization utilizing a nucleic probe according to the
invention. This probe will advantageously be labeled with a
nonradioactive (cold probe) or radioactive isotope.
[0228] For the purposes of the present invention, "DNA of the
biological sample" or "DNA contained in the biological sample" will
be understood as meaning either the DNA present in the biological
sample considered, or possibly the cDNA obtained after the action
of an enzyme of reverse transcriptase type on the RNA present in
the biological sample.
[0229] A further embodiment of the invention comprises a method,
characterized in that it comprises the following acts: a)
contacting of a nucleotide probe according to the invention with a
biological sample, the DNA contained in the biological sample
having, if need be, previously been made accessible to
hybridization under conditions allowing the hybridization of the
nucleotide probe with the DNA of the sample; and b) demonstration
of the hybrid formed between the nucleotide probe and the DNA of
the biological sample.
[0230] The present invention also relates to a procedure according
to the invention, characterized in that it comprises the following
acts: a) contacting of a nucleotide probe immobilized on a support
according to the invention with a biological sample, the DNA of the
sample having, if need be, previously been made accessible to
hybridization, under conditions allowing the hybridization of the
nucleotide probe with the DNA of the sample; b) contacting of the
hybrid formed between the nucleotide probe immobilized on a support
and the DNA contained in the biological sample, if need be, after
elimination of the DNA of the biological sample that has not
hybridized with the nucleotide probe, with a nucleotide probe
labeled according to the invention; c) demonstration of the novel
hybrid formed in act b).
[0231] According to an advantageous embodiment of the procedure for
detection and/or identification defined previously, this is
characterized in that, prior to act a), the DNA of the biological
sample is first amplified with the aid of at least one primer
according to the invention.
[0232] Embodiments of methods include methods of altering secondary
metabolism in a cell, the methods comprising providing a
recombinant, purified, and/or isolated nucleotide sequence
comprising a nucleotide sequence selected from the group consisting
of a nucleotide sequence having at least 90% sequence identity to
at least one of the sequences of SEQ ID NOS:2, 19, 36, 53, 70, 87,
104, 121, 138, 155, 172, 189, 206, 223, 240, 257, 274, 291, 308,
325, 342, 359, 376, 393, 410, 427, 444, 461, 478, 495, 512, 529,
546, 563, 580, 597, 614, 631, 648, 665, 682, 699, 716, 733, 750,
767, 784, 801, 818, 835, 852, 869, 886, 903, 920, 937, 954, 971,
988, 1005, 1022, 1039, 1056, 1073, 1090, 1107, 1124, 1141, 1158,
1175, 1192, 1209, 1226, 1243, 1260, 1277, 1294, 1311, 1328, 1345,
1362, 1379, 1396, 1413, 1430, 1447, 1464, 1481, 1498, 1515, 1532,
1549, and 1566 and/or a recombinant, purified, and/or isolated
polypeptide selected from the group consisting of a polypeptide
having at least 90% sequence identity to at least one of the
sequences of SEQ ID NOS:1, 18, 35, 52, 69, 86, 103, 120, 137, 154,
171, 188, 205, 222, 239, 256, 273, 290, 307, 324, 341, 358, 375,
392, 409, 426, 443, 460, 477, 494, 511, 528, 545, 562, 579, 596,
613, 630, 647, 664, 681, 698, 715, 732, 749, 766, 783, 800, 817,
834, 851, 868, 885, 902, 819, 936, 953, 970, 987, 1004, 1021, 1038,
1055, 1072, 1089, 1106, 1123, 1140, 1157, 1174, 1191, 1208, 1225,
1242, 1259, 1276, 1293, 1310, 1327, 1344, 1361, 1378, 1395, 1412,
1429, 1446, 1463, 1480, 1497, 1514, 1531, 1548, and 1565 to the
cell.
[0233] Further embodiments of methods include placing a cell
producing or encoding a recombinant, purified, and/or isolated
nucleotide sequence comprising a nucleotide sequence selected from
the group consisting of a nucleotide sequence having at least 90%
sequence identity to at least one of the sequences of SEQ ID NOS:2,
19, 36, 53, 70, 87, 104, 121, 138, 155, 172, 189, 206, 223, 240,
257, 274, 291, 308, 325, 342, 359, 376, 393, 410, 427, 444, 461,
478, 495, 512, 529, 546, 563, 580, 597, 614, 631, 648, 665, 682,
699, 716, 733, 750, 767, 784, 801, 818, 835, 852, 869, 886, 903,
920, 937, 954, 971, 988, 1005, 1022, 1039, 1056, 1073, 1090, 1107,
1124, 1141, 1158, 1175, 1192, 1209, 1226, 1243, 1260, 1277, 1294,
1311, 1328, 1345, 1362, 1379, 1396, 1413, 1430, 1447, 1464, 1481,
1498, 1515, 1532, 1549, and 1566 and/or a recombinant, purified,
and/or isolated polypeptide selected from the group consisting of a
polypeptide having at least 90% sequence identity to at least one
of the sequences of SEQ ID NOS:1, 18, 35, 52, 69, 86, 103, 120,
137, 154, 171, 188, 205, 222, 239, 256, 273, 290, 307, 324, 341,
358, 375, 392, 409, 426, 443, 460, 477, 494, 511, 528, 545, 562,
579, 596, 613, 630, 647, 664, 681, 698, 715, 732, 749, 766, 783,
800, 817, 834, 851, 868, 885, 902, 819, 936, 953, 970, 987, 1004,
1021, 1038, 1055, 1072, 1089, 1106, 1123, 1140, 1157, 1174, 1191,
1208, 1225, 1242, 1259, 1276, 1293, 1310, 1327, 1344, 1361, 1378,
1395, 1412, 1429, 1446, 1463, 1480, 1497, 1514, 1531, 1548, and
1565 in an environment comprising temperatures at or above about
25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, and/or 95
degrees Celsius and/or a pH at, below, and/or above 8, 7, 6, 5, 4,
3, 2, 1, and/or 0.
[0234] The present invention provides cells that have been
genetically manipulated to have an altered capacity to produce
expressed proteins. In particular, the present invention relates to
Gram-positive microorganisms, such as Bacillus species having
enhanced expression of a protein of interest, wherein one or more
chromosomal genes have been inactivated, and/or wherein one or more
chromosomal genes have been deleted from the Bacillus chromosome.
In some further embodiments, one or more indigenous chromosomal
regions have been deleted from a corresponding wild-type Bacillus
host chromosome. In further embodiments, the Bacillus is an
Alicyclobacillus sp. or Alicyclobacillus acidocaldarius.
[0235] Additional embodiments, include methods of modulating
metabolism at temperatures at or above about 25, 30, 35, 40, 45,
50, 55, 60, 65, 70, 75, 80, 85, 90, and/or 95 degrees Celsius
and/or at a pH at, below, and/or above 8, 7, 6, 5, 4, 3, 2, 1,
and/or 0 via providing a recombinant, purified, and/or isolated
nucleotide sequence comprising a nucleotide sequence selected from
the group consisting of a nucleotide sequence having at least 90%
sequence identity to at least one of the sequences of SEQ ID NOS:2,
19, 36, 53, 70, 87, 104, 121, 138, 155, 172, 189, 206, 223, 240,
257, 274, 291, 308, 325, 342, 359, 376, 393, 410, 427, 444, 461,
478, 495, 512, 529, 546, 563, 580, 597, 614, 631, 648, 665, 682,
699, 716, 733, 750, 767, 784, 801, 81R, 835, R52, 869, 886, 903,
920, 937, 954, 971, 988, 1005, 1022, 1039, 1056, 1073, 1090, 1107,
1124, 1141, 1158, 1175, 1192, 1209, 1226, 1243, 1260, 1277, 1294,
1311, 1328, 1345, 1362, 1379, 1396, 1413, 1430, 1447, 1464, 1481,
1498, 1515, 1532, 1549, and 1566 and/or a recombinant, purified,
and/or isolated polypeptide selected from the group consisting of a
polypeptide having at least 90% sequence identity to at least one
of the sequences of SEQ ID NOS:1, 18, 35, 52, 69, 86, 103, 120,
137, 154, 171, 188, 205, 222, 239, 256, 273, 290, 307, 324, 341,
358, 375, 392, 409, 426, 443, 460, 477, 494, 511, 528, 545, 562,
579, 596, 613, 630, 647, 664, 681, 698, 715, 732, 749, 766, 783,
800, 817, 834, 851, 868, 885, 902, 819, 936, 953, 970, 987, 1004,
1021, 1038, 1055, 1072, 1089, 1106, 1123, 1140, 1157, 1174, 1191,
1208, 1225, 1242, 1259, 1276, 1293, 1310, 1327, 1344, 1361, 1378,
1395, 1412, 1429, 1446, 1463, 1480, 1497, 1514, 1531, 1548, and
1565 to a cell.
[0236] In embodiments of the invention any one of the isolated
and/or purified polypeptides according to the invention may be
enzymatically or functionally active at temperatures at or above
about 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90,
and/or 95 degrees Celsius and/or may be enzymatically or
functionally active at a pH at, below, and/or above 8, 7, 6, 5, 4,
3, 2, 1, and/or 0. In further embodiments of the invention,
glycosylation, pegylation, and/or other post-translational
modification may be required for the isolated and/or purified
polypeptides according to the invention to be enzymatically or
functionally active at a pH at or below 8, 7, 6, 5, 4, 3, 2, 1,
and/or 0 or at temperatures at or above about 25, 30, 35, 40, 45,
50, 55, 60, 65, 70, 75, 80, 85, 90, and/or 95 degrees Celsius.
[0237] The invention is described in additional detail in the
following illustrative examples. Although the examples may
represent only selected embodiments of the invention, it should be
understood that the following examples are illustrative and not
limiting.
EXAMPLES
Example 1
Modulating or Altering Metabolism Using Nucleotide and Amino Acid
Sequences from Alicyclobacillus acidocaldarius
[0238] Provided in SEQ ID NOS:2, 19, 36, 53, 70, 87, 104, 121, 138,
155, 172, 189, 206, 223, 240, 257, 274, 291, 308, 325, 342, 359,
376, 393, 410, 427, 444, 461, 478, 495, 512, 529, 546, 563, 580,
597, 614, 631, 648, 665, 682, 699, 716, 733, 750, 767, 784, 801,
818, 835, 852, 869, 886, 903, 920, 937, 954, 971, 988, 1005, 1022,
1039, 1056, 1073, 1090, 1107, 1124, 1141, 1158, 1175, 1192, 1209,
1226, 1243, 1260, 1277, 1294, 1311, 1328, 1345, 1362, 1379, 1396,
1413, 1430, 1447, 1464, 1481, 1498, 1515, 1532, 1549, and 1566 are
a nucleotide sequence isolated from Alicyclobacillus acidocaldarius
and coding for the polypeptides of SEQ ID NOS:1, 18, 35, 52, 69,
86, 103, 120, 137, 154, 171, 188, 205, 222, 239, 256, 273, 290,
307, 324, 341, 358, 375, 392, 409, 426, 443, 460, 477, 494, 511,
528, 545, 562, 579, 596, 613, 630, 647, 664, 681, 698, 715, 732,
749, 766, 783, 800, 817, 834, 851, 868, 885, 902, 819, 936, 953,
970, 987, 1004, 1021, 1038, 1055, 1072, 1089, 1106, 1123, 1140,
1157, 1174, 1191, 1208, 1225, 1242, 1259, 1276, 1293, 1310, 1327,
1144, 1361, 1378, 1395, 1412, 1429, 1446, 1463, 1480, 1497, 1514,
1531, 1548, and 1565, respectively. The nucleotide sequences of SEQ
ID NOS:2, 19, 36, 53, 70, 87, 104, 121, 138, 155, 172, 189, 206,
223, 240, 257, 274, 291, 308, 325, 342, 359, 376, 393, 410, 427,
444, 461, 478, 495, 512, 529, 546, 563, 580, 597, 614, 631, 648,
665, 682, 699, 716, 733, 750, 767, 784, 801, 818, 835, 852, 869,
886, 903, 920, 937, 954, 971, 988, 1005, 1022, 1039, 1056, 1073,
1090, 1107, 1124, 1141, 1158, 1175, 1192, 1209, 1226, 1243, 1260,
1277, 1294, 1311, 1328, 1345, 1362, 1379, 1396, 1413, 1430, 1447,
1464, 1481, 1498, 1515, 1532, 1549, and 1566 are placed into
expression vectors using techniques standard in the art. The
vectors are then provided to cells such as bacteria cells or
eukaryotic cells such as Sf9 cells or CHO cells. In conjunction
with the normal machinery in present in the cells, the vectors
comprising SEQ ID NOS:2, 19, 36, 53, 70, 87, 104, 121, 138, 155,
172, 189, 206, 223, 240, 257, 274, 291, 308, 325, 342, 359, 376,
393, 410, 427, 444, 461, 478, 495, 512, 529, 546, 563, 580, 597,
614, 631, 648, 665, 682, 699, 716, 733, 750, 767, 784, 801, 818,
835, 852, 869, 886, 903, 920, 937, 954, 971, 988, 1005, 1022, 1039,
1056, 1073, 1090, 1107, 1124, 1141, 1158, 1175, 1192, 1209, 1226,
1243, 1260, 1277, 1294, 1311, 1328, 1345, 1362, 1379, 1396, 1413,
1430, 1447, 1464, 1481, 1498, 1515, 1532, 1549, and 1566 produce
the polypeptides of SEQ ID NOS:1, 18, 35, 52, 69, 86, 103, 120,
137, 154, 171, 188, 205, 222, 239, 256, 273, 290, 307, 324, 341,
358, 375, 392, 409, 426, 443, 460, 477, 494, 511, 528, 545, 562,
579, 596, 613, 630, 647, 664, 681, 698, 715, 732, 749, 766, 783,
800, 817, 834, 851, 868, 885, 902, 819, 936, 953, 970, 987, 1004,
1021, 1038, 1055, 1072, 1089, 1106, 1123, 1140, 1157, 1174, 1191,
1208, 1225, 1242, 1259, 1276, 1293, 1310, 1327, 1344, 1361, 1378,
1395, 1412, 1429, 1446, 1463, 1480, 1497, 1514, 1531, 1548, and
1565. The polypeptides of SEQ ID NOS:1, 18, 35, 52, 69, 86, 103,
120, 137, 154, 171, 188, 205, 222, 239, 256, 273, 290, 307, 324,
341, 358, 375, 392, 409, 426, 443, 460, 477, 494, 511, 528, 545,
562, 579, 596, 613, 630, 647, 664, 681, 698, 715, 732, 749, 766,
783, 800, 817, 834, 851, 868, 885, 902, 819, 936, 953, 970, 987,
1004, 1021, 1038, 1055, 1072, 1089, 1106, 1123, 1140, 1157, 1174,
1191, 1208, 1225, 1242, 1259, 1276, 1293, 1310, 1327, 1344, 1361,
1378, 1395, 1412, 1429, 1446, 1463, 1480, 1497, 1514, 1531, 1548,
and 1565 are then isolated and/or purified. The isolated and/or
purified polypeptides of SEQ ID NOS:1, 18, 35, 52, 69, 86, 103,
120, 137, 154, 171, 188, 205, 222, 239, 256, 273, 290, 307, 324,
341, 358, 375, 392, 409, 426, 443, 460, 477, 494, 511, 528, 545,
562, 579, 596, 613, 630, 647, 664, 681, 698, 715, 732, 749, 766,
783, 800, 817, 834, 851, 868, 885, 902, 819, 936, 953, 970, 987,
1004, 1021, 1038, 1055, 1072, 1089, 1106, 1123, 1140, 1157, 1174,
1191, 1208, 1225, 1242, 1259, 1276, 1293, 1310, 1327, 1344, 1361,
1378, 1395, 1412, 1429, 1446, 1463, 1480, 1497, 1514, 1531, 1548,
and 1565 are then each demonstrated to have one or more of the
activities provided in Table 1.
[0239] The isolated and/or purified polypeptides of SEQ ID NOS:1,
18, 35, 52, 69, 86, 103, 120, 137, 154, 171, 188, 205, 222, 239,
256, 273, 290, 307, 324, 341, 358, 375, 392, 409, 426, 443, 460,
477, 494, 511, 528, 545, 562, 579, 596, 613, 630, 647, 664, 681,
698, 715, 732, 749, 766, 783, 800, 817, 834, 851, 868, 885, 902,
819, 936, 953, 970, 987, 1004, 1021, 1038, 1055, 1072, 1089, 1106,
1123, 1140, 1157, 1174, 1191, 1208, 1225, 1242, 1259, 1276, 1293,
1310, 1327, 1344, 1361, 1378, 1395, 1412, 1429, 1446, 1463, 1480,
1497, 1514, 1531, 1548, and 1565 are demonstrated to have activity
as at least one of a (S)-2-hydroxy-acid oxidase,
[acyl-carrier-protein] S-malonyltransferase, 1,3-propanediol
Dehydrogenase, 2-isopropylmalate Synthase, 3-hydroxybutyryl-CoA
dehydratase, 3-isopropylmalate Dehydratase, 3-isopropylmalate
Dehydrogenase, 3-oxoacid CoA-transferase, 8-amino-7-oxononanoate
Synthase, Acetaldehyde dehydrogenase (acetylating), Acetate-CoA
ligase, Acetolactate synthase, Acetyl-CoA C-acetyltransferase,
Aconitate hydratase, Alcohol dehydrogenase, Alcohol dehydrogenase
(NADP+), Aldehyde dehydrogenase, Aldehyde dehydrogenase (NAD+), ATP
phosphoribosyltransferase, ATP synthase alpha chain, ATP synthase B
chain, ATP synthase beta chain, ATP synthase C chain, ATP synthase
epsilon chain, ATP synthase gamma chain, Biotin synthase,
Branched-chain-amino-acid transaminase, Butyryl-CoA dehydrogenase,
Citrate (Si)-synthase, Dethiobiotin synthase, Diaminopimelate
decarboxylase, Diaminopimelate epimerase, Dihydrodipicolinate
reductase, Dihydrodipicolinate synthase, Dihydrolipoyl
dehydrogenase, Dihydroxy-acid dehydratase, Enoyl-CoA hydratase,
FdhD protein (fdsC), Formate dehydrogenase, Glycerate kinase,
Glycine hydroxymethyltransferase, Isocitrate lyase, Lactaldehyde
reductase, Lactate 2-monooxygenase, L-lactate dehydrogenase, Malate
dehydrogenase, Malate dehydrogenase (acceptor), Malate
dehydrogenase (oxaloacetate-decarboxylating), Malate synthase,
Malonate-semialdehyde dehydrogenase (acetylating),
Methylmalonate-semialdehyde dehydrogenase (acylating),
N-acetyldiaminopimelate deacetylase, Oxoglutarate dehydrogenase
(succinyl-transferring), Phosphoenolpyruvate carboxylase,
Phosphoglycerate dehydrogenase, Phosphoribosylanthranilate
isomerase, Pyruvate dehydrogenase (acetyl-transferring), Pyruvate,
phosphate dikinase, Succinate dehydrogenase cytochrome b558
subunit, Succinate dehydrogenase flavoprotein subunit, Succinate
dehydrogenase iron-sulfur protein, and Succinate-CoA ligase
(ADP-forming).
[0240] While this invention has been described in certain
embodiments, the present invention can be further modified within
the spirit and scope of this disclosure. This application is
therefore intended to cover any variations, uses, or adaptations of
the invention using its general principles. Further, this
application is intended to cover such departures from the present
disclosure as come within known or customary practice in the art to
which this invention pertains and that fall within the limits of
the appended claims and their legal equivalents.
[0241] All references, including publications, patents, and patent
applications, cited herein are hereby incorporated by reference to
the same extent as if each reference were individually and
specifically indicated to be incorporated by reference and were set
forth in its entirety herein.
[0242] While this invention has been described in certain
embodiments, the present invention can be further modified within
the spirit and scope of this disclosure. This application is
therefore intended to cover any variations, uses, or adaptations of
the invention using its general principles. Further, this
application is intended to cover such departures from the present
disclosure as come within known or customary practice in the art to
which this invention pertains and that fall within the limits of
the appended claims and their legal equivalents.
BIBLIOGRAPHIC REFERENCES
[0243] Barany, F., 1991, PNAS USA, 88:189-193. [0244] Buckholz, R.
G., 1993, Yeast systems for the expression of heterologous gene
products. Curr. Op. Biotechnology 4:538-542. [0245] Burg, J. L. et
al., 1996, Mol. and Cell. Probes, 10:257-271. [0246] Chu, B. C. F.
et al., 1986, NAR, 14:5591-5603. [0247] Duck, P. et al., 1990,
Biotechniques, 9:142-147. [0248] Edwards, C. P., and Aruffo, A.,
1993, Current applications of COS cell based transient expression
systems, Curr. Op. Biotechnology 4:558-563. [0249] Guateli, J. C.
et al., 1990, PNAS USA, 87:1874-1878. [0250] Houben-Weyl, 1974, in
Methoden der Organischen Chemie, E. Wunsch Ed., Volume 15-I and
15-II, Thieme, Stuttgart. [0251] Innis, M. A. et al., 1990, in PCR
Protocols, A guide to Methods and Applications, San Diego, [0252]
Academic Press. [0253] Kievitis, T. et al., 1991, J. Virol.
Methods, 35:273-286. [0254] Kohler, G. et al., 1975, Nature,
256(5517):495-497. [0255] Kwoh, D. Y. et al., 1989, PNAS USA,
86:1173-1177. [0256] Luckow, V. A., 1993, Baculovirus systems for
the expression of human gene products. Curr. Op. Biotechnology
4:564-572. [0257] Matthews, J. A. et al., 1988, Anal. Biochem.,
169:1-25. [0258] Merrifield, R. D., 1966, J. Am. Chem. Soc.,
88(21):5051-5052. [0259] Miele, E. A. et al., 1983, J. Mol. Biol.,
171:281-295. [0260] Olins, P. O., and Lee, S. C., 1993, Recent
advances in heterologous gene expression in E. coli. Curr Op.
Biotechnology 4:520-525. [0261] Rolfs, A. et al., 1991, In PCR
Topics, Usage of Polymerase Chain reaction in Genetic and
Infectious Disease, Berlin: Springer-Verlag. [0262] Sambrook, J. et
al., 1989, In Molecular Cloning: A Laboratory Manual. Cold Spring
Harbor, N.Y.: Cold Spring Harbor Laboratory Press. [0263]
Sanchez-Pescador, R., 1988, J. Clin. Microbiol., 26(10):1934-1938.
[0264] Segev D., 1992, in "Non-radioactive Labeling and Detection
of Biomolecules," Kessler C. Springer-Verlag, Berlin, New-York:
197-205. [0265] Urdea, M. S., 1988, Nucleic Acids Research,
11:4937-4957. [0266] Walker, G. T. et al., 1992, NAR 20:1691-1696.
[0267] Walker, G. T. et al., 1992, PNAS USA, 89:392-396. [0268]
White, B. A. et al., 1997, Methods in Molecular Biology, 67, Humana
Press, Totowa, N.J.
Sequence CWU 0 SQTB SEQUENCE LISTING The patent application
contains a lengthy "Sequence Listing" section. A copy of the
"Sequence Listing" is available in electronic form from the USPTO
web site
(http://seqdata.uspto.gov/?pageRequest=docDetail&DocID=US20160046911A1).
An electronic copy of the "Sequence Listing" will also be available
from the USPTO upon request and payment of the fee set forth in 37
CFR 1.19(b)(3).
0 SQTB SEQUENCE LISTING The patent application contains a lengthy
"Sequence Listing" section. A copy of the "Sequence Listing" is
available in electronic form from the USPTO web site
(http://seqdata.uspto.gov/?pageRequest=docDetail&DocID=US20160046911A1).
An electronic copy of the "Sequence Listing" will also be available
from the USPTO upon request and payment of the fee set forth in 37
CFR 1.19(b)(3).
* * * * *
References